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ABSTRACT 
Multiple myeloma (MM), Waldenstrom’s macroglobulinemia (WM), and monoclonal 
gammopathy of undetermined significance (MGUS) are B cell conditions associated 
with suppressed immune functions and susceptibility to infection. Severe pneumococcal 
disease is common not least in MM patients and vaccination is considered important, 
although the protective efficacy is debated. The aims of the first two studies of this 
thesis were to investigate humoral immunity to a spectrum of prevalent pathogens, and 
responses to pneumococcal vaccination with either a 23-valent polysaccharide vaccine 
or a 7-valent conjugated vaccine in elderly patients with MM, WM, and MGUS. We 
further compared two methods for evaluation of pneumococcal vaccine responses, 
serotype-specific ELISA and opsonophagocytosis (OPA) in the same groups of patients, 
and retrospectively examined the prevalence of respiratory viruses in MM. Background 
antibody levels to pathogens were most depressed in MM but low antibody levels were 
also seen in WM and MGUS compared to age-matched controls. Pneumococci, 
Staphylococcus aureus, varicella zoster virus, and fungi (Candida, Aspergillus) were 
identified as risk pathogens, while immunity to Haemophilus influenzae and most viruses 
was retained in all study groups. Likewise, responses to pneumococcal vaccination were 
suppressed in all three patient categories. No differences between the vaccine types 
given as single doses were found. Pneumococcal antibody titers as measured by ELISA 
and OPA correlated very poorly in MM and WM patients, and our data indicate that 
ELISA measurements may overestimate anti-pneumococcal immunity in these patients. 
Rhinovirus, influenza virus and respiratory syncytial virus were the most commonly 
detected respiratory viruses in the investigated MM cohort. Patients with virus-positive 
tests were younger and had shorter disease duration than patients with negative analyses. 
In summary, patients with MM, WM and MGUS have a suppressed humoral immunity 
to many common pathogens, foremost bacteria. Reduced responses to pneumococcal 
vaccination can be expected in these patients. The use of an OPA method should be 
preferred for evaluating pneumococcal vaccine responses in B cell malignancies. 
Keywords: Multiple myeloma, Waldenstrom’s macroglobulinemia, MGUS, elderly, 
immunity, infection, pneumococcal vaccination, ELISA, opsonophagocytosis                                    
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Sammanfattning 
Multipelt myelom, Waldenströms makroglobulinemi (WM) och monoklonal gammopati 
av oklar signifikans (MGUS) är tillstånd som drabbar immunförsvarets B-celler. Medan 
multipelt myelom och WM är blodcancerformer är MGUS ett icke malignt (elakartat) 
tillstånd, som dock kan vidareutvecklas till en malign sjukdom, i första hand myelom 
eller WM. Dessa tillstånd drabbar huvudsakligen äldre personer, och medelåldern för 
insjuknande i myelom och WM är 70 år. Multipelt myelom är en av de vanligaste 
blodcancerformerna medan WM endast drabbar ca 4 personer per miljon invånare. 
MGUS kan påvisas hos 3% av befolkningen över 50 år med en ökande incidens vid 
ökande ålder. Tillstånden karakteriseras av en tillväxande klon av B-celler som alla 
producerar likadana antikroppar, oftast icke-funktionella, den så kallade M-
komponenten. Denna klon av B-celler tränger undan friska B-celler, vilket får till följd 
att en minskad mängd funktionella antikroppar produceras. Detta parallellt med 
tillkomst av andra defekter i immunförsvaret gör patienterna infektionskänsliga, och 
infektioner är en av de vanligaste dödsorsakerna vid multipelt myelom. En ökad 
sjuklighet och dödlighet i infektioner har även visats för WM och MGUS.  
Kapselförsedda bakterier såsom pneumokocker är viktiga sjukdomsalstrare vid B-
cellssjukdomar. Pneumokocker orsakar i första hand lunginflammation men så kallade 
invasiva infektioner, blodförgiftning och hjärnhinneinflammation, är inte ovanliga och 
dödligheten i dessa är hög i synnerhet hos äldre personer. Vaccination mot 
pneumokocker ingår sedan 2009 i det svenska barnvaccinationsprogrammet och har lett 
till betydande minskning av svåra pneumokockinfektioner i samhället. Pneumokock-
vaccination rekommenderas också till riskgrupper, såsom äldre och personer med 
försämrat immunförsvar (där B-cellssjukdomar ingår). Dock har ett nedsatt 
vaccinationssvar tidigare setts inte minst hos personer med multipelt myelom. 
I denna avhandling studeras infektionskänslighet samt vaccinationssvar mot 
pneumokocker hos äldre (> 60 år) västsvenska patienter med ovan nämnda diagnoser. I 
det första delarbetet har vi mätt bakgrundsnivåer av antikroppar i blodet mot ett stort 
antal bakterier, virus och svampar hos patienterna och jämfört med en åldersmatchad 
kontrollgrupp utan blodsjukdom. Syftet var att undersöka om och hur immunförsvaret 
är nedsatt i de tre sjukdomsgrupperna och att identifiera smittämnen som dessa 
patienter har ett tydligt nedsatt skydd emot. I delarbete II undersöks svaret på 
pneumokockvaccination hos samma patienter. Vaccin mot pneumokocker finns av två 
principiellt skilda typer, dels polysackaridvaccin, vilket varit standardvaccinet till vuxna, 
dels konjugatvaccin, som utvecklats för att ge ett gott vaccinationsskydd hos små barn. 
Det sistnämnda har i vissa studier visat en bättre effekt även hos äldre och personer med 
nedsättning av immunförsvaret. Vi ville därför jämföra de två vaccinerna i våra 
patientgrupper. I det tredje delarbetet jämförs två metoder för utvärdering av vaccinsvar 
mot pneumokocker, antikroppsmätning med standardmetoden ELISA och en 
funktionell analys, opsonofagocytos (OPA), där man mäter hur väl patientens blod 
avdödar bakterierna. Det fjärde delarbetet ägnas enbart åt patienter med multipelt 
myelom, hos vilka vi retrospektivt studerat förekomsten av luftvägsvirus i samband med 
luftvägssymtom. Vi ville också undersöka om man kunde finna en koppling mellan 
positivt virustest och andra faktorer som sjukhusvård, dödlighet, ålder och 
sjukdomsaktivitet. 
Påtagligt sänkta antikroppsnivåer mot ett flertal smittämnen påvisades hos patienter med 
multipelt myelom, men även de övriga två patientgrupperna hade lägre nivåer än 
kontrollgruppen. Detta var mest påtagligt för pneumokocker och gula stafylokocker 
(hudbakterier) liksom för vattkoppsvirus och svampar. Tvärtom förelåg bibehållna 
antikroppsnivåer mot flertalet virus i alla patientgrupper. I samtliga patientgrupper sågs 
också ett nedsatt vaccinationssvar mot pneumokocker, mest uttalat hos myelom-
patienterna. Vi kunde inte påvisa någon skillnad i svaret på de två olika vaccintyperna 
givna som enkeldos för någon av studiegrupperna inklusive kontrollgruppen. 
Överensstämmelsen mellan de två metoderna för mätning av vaccinationssvar mot 
pneumokocker var god i kontrollgruppen och hos patienter med MGUS men mycket 
dålig hos patienter med myelom och WM. Våra data inger misstanke om falskt höga 
antikroppsnivåer mätt med ELISA hos vissa av dessa patienter, och vi rekommenderar 
därför inte ELISA vid dessa diagnoser. De oftast påvisade luftvägsvirusen i den 
undersökta kohorten av myelompatienter var rhinovirus, influensavirus och 
respiratoriskt syncytievirus (RS). Patienter med positivt virustest var yngre och hade 
kortare sjukdomsduration än patienter med negativ analys. 
Sammanfattningsvis visar dessa studier ett nedsatt antikroppsskydd mot ett flertal 
vanliga smittämnen, framför allt bakterier, samt ett nedsatt vaccinationssvar mot 
pneumokocker hos patienter med multipelt myelom, Waldenströms makroglobulinemi 
och MGUS. Vid mätning av pneumokockvaccinationssvar hos patienter med myelom 
och WM är en funktionell OPA-analys att föredra framför ELISA.   
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1 Introduction 
Multiple myeloma, Waldenstrom’s macroglobulinemia, and monoclonal gammopathy of 
undetermined significance (MGUS) are conditions that belong to the monoclonal 
gammopathies. This group of disorders is defined by the expansion in the bone marrow 
of a single clone of B cells, which in its turn produces the disease-defining homogenous 
M- (monoclonal) protein that can be detected in the blood.1, 2 The M-protein consists of 
identical antibodies of the IgG, IgA, IgM, IgD, or IgE isotype, and the size of the clone 
is a marker of the disease burden. Multiple myeloma and Waldenstrom’s macro-
globulinemia are malignant conditions. In contrast, MGUS is characterized by the 
presence of a low level of M-protein but no clinical signs of malignant disease; it may, 
however, progress into a malignant state, most commonly multiple myeloma or 
Waldenstrom’s macroglobulinemia.1 Conversely, virtually all cases of multiple myeloma 
are preceded by MGUS.3  
Patients with B cell malignancies and disorders are immune deficient and have an 
increased susceptibility to and mortality in infections.4-6 Their immunosuppression 
derives from the displacement of non-malignant B cells and concomitantly reduced 
levels of functional antibodies, abnormalities of other cell lines of the acquired and 
innate immune systems, as well as treatment-induced suppression of immune functions.  
Several studies have shown an increased incidence of infections such as pneumonia, 
sepsis, influenza, and herpes zoster as well as a diversity of autoimmune and 
inflammatory disorders in patients who have subsequently been diagnosed with multiple 
myeloma, Waldenstrom’s macroglobulinemia, or MGUS.7-10 This could indicate an 
underlying immune disturbance present several years before the hematological diagnosis 
but also raises the possibility that immune-related conditions may act as triggers for the 
development of a B cell malignancy or disorder.   
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1.1 Multiple myeloma 
Multiple myeloma is a disease of long history. Bone lesions suggestive of the diagnosis 
have been identified in skeletons of several thousand years of age in Egypt and 
European countries.11 The first documented cases of multiple myeloma were described 
in the middle of the 19th century in patients suffering from fatigue, back pain, repeated 
fractures, and peripheral edema. The myeloma-specific proteinuria was described by 
Henry Bence Jones in 1848. Half a decade later, the characteristics of plasma cells were 
known and this type of cell was defined as the proliferating cell line in myeloma.11 The 
Swedish hematologist Jan Waldenström first described the M-protein typical of multiple 
myeloma and other monoclonal gammopathies, seen as a narrow band on serum-
electrophoresis.12   
 
 
 
 
 
 (A) Plasmacytosis in bone marrow. (B) Serum-electrophoresis showing a narrow band in the  Figure 1.
region indicative of the presence of a monoclonal (M-) protein. (C) Vertebral osteolytic bone lesions (black) on 
PET-CT. Figures (A) and (C) are reproduced and adapted with permission of the WJG Press and 
Baishideng.13 Figure (B) is used with permission from Wiley and sons.1 
Multiple myeloma is the second most common hematological malignancy after 
lymphoma. It accounts for 10-15% of hematological cancer and 1% of all types of 
malignancy,14 and has an incidence of about 6 cases per 100.000 inhabitants in Sweden.15 
The incidence increases with age, and patients under the age of 40 are very rare. The 
median age at diagnosis is about 70 years. Multiple myeloma is somewhat more 
common in males than in females.14, 16 
1.1.1 Definition 
A diagnosis of multiple myeloma requires the presence of at least 10% of clonal bone 
marrow plasma cells or extramedullary clonal plasma cells in a biopsy (plasmacytoma) 
and one or more myeloma-defining events. These events represent end-organ damage 
that can be attributed to the underlying plasma cell disorder and include hypercalcemia, 
renal insufficiency, anemia, and osteolytic bone lesions on skeletal radiography.17 
Although most patients with multiple myeloma present with symptoms, the disease can 
in an early stage be silent, so called smouldering myeloma. This state is defined by serum 
A B C 
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M-protein > 30 g/L and/or clonal bone marrow plasma cells ≥ 10% but absence of 
myeloma-defining events.17 The M-protein secreted in multiple myeloma is commonly 
of the IgG, IgA or IgD isotype, or consists only of immunoglobulin free light chains ( 
and )Non-secretory myeloma are also seen.14 
1.1.2 Clinical features 
Skeletal pain is the most common symptom of multiple myeloma. It is a result of plasma 
cell infiltration of the bone marrow causing osteolytic lesions and pathological 
fractures.15 The bone resorption often results in hypercalcemia which, together with 
toxic effects of immunoglobulin light chains, causes renal failure. This is seen in about 
25% of patients at diagnosis and might require dialysis.4 Fatigue is another common 
symptom usually related to anemia, which is found in about 70% of patients at diagnosis 
and is caused by the bone marrow infiltration of plasma cells. This might also lead to 
neutropenia and thrombocytopenia.14 Recurrent and severe infections are seen in many 
patients especially during progressive disease.4, 18, 19 
1.1.3 Treatment and prognosis 
There is no curative treatment for multiple myeloma but treatment options have greatly 
improved during the last 20 years and resulted in prolonged periods of remission and 
survival.20 Despite this, overall survival in multiple myeloma is only 4-5 years.21 Renal 
failure, male sex, and high age are associated with a poorer prognosis.4, 16 The indication 
for treatment is symptomatic disease (or high-risk smouldering myeloma as defined by 
biomarkers). High-dose melphalan with autologous stem cell transplantation (ASCT) is 
the established treatment for patients younger than 65-70 years since the end of the 
1990s. This was the first break-through in the treatment of multiple myeloma since the 
1960s and has been followed by the introduction of immunomodulatory drugs (IMiDs) 
such as thalidomide and lenalidomide and the proteasome inhibitors bortezomib and 
carfilzomib. For elderly patients, various combinations of chemotherapy and 
corticosteroids, often melphalan and prednisone (MP), and any of the new drugs are 
used. At relapse, ASCT can be repeated if the patient responded well the first time with 
a long so called plateau phase without signs of organ damage or symptoms. Otherwise 
various combinations of chemotherapy and new drugs are used.15 
1.2 Waldenstrom’s macroglobulinemia 
Waldenstrom’s macroglobulinemia (WM) is named after Jan Waldenström, who made 
the original description of the disease in 1944 and reported two patients with oronasal 
bleeding, lymphadenopathy, anemia, thrombocytopenia, hyperviscosity, and an elevated 
erythrocyte sedimentation rate.22 The condition is classified as a lymphoplasmacytic 
lymphoma with an IgM monoclonal gammopathy.23 WM is a rare disease with an 
incidence of about 4 cases per million inhabitants.24 It constitutes 1-2% of all 
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hematological malignancies.25 The median age at diagnosis is around 70 years, and the 
incidence is twice as high in men as in women. Familial cases of WM have been 
reported and have been associated with a high incidence of autoimmune disorders.26, 27 
Also, an increased risk of WM has been described for patients with various infections in 
their personal history suggesting that chronic immune stimulation may be associated 
with the development of the disease besides genetic factors.9 
 
 
 
 
 
 
 
 Jan Waldenström 1963. Reprinted with permission of Elsevier.28 Figure 2.
1.2.1 Definition 
WM is a lymphoproliferative tumor defined by the infiltration of clonal lympho-
plasmacytic cells (small B lymphocytes) in the bone marrow and sometimes in other 
lymphatic tissues such as lymph nodes and the spleen, with the presence of a 
monoclonal immunoglobulin (M-protein) of IgM-type in the blood.2, 23 Since these 
criteria do not define a specific level of M-protein and tumor cell infiltration of the bone 
marrow, and many patients are asymptomatic at diagnosis, the distinction between IgM 
MGUS and WM is not evident but more of a continuum.29 
1.2.2 Clinical features 
Presenting symptoms are in many cases related to tumor infiltration, and fatigue, weight 
loss and anemia are common.25 Thrombocytopenia causes nose bleeds and petecchiae. 
Hepato-splenomegaly and lymphadenopathy are common. Hyperviscosity is a central 
feature and is caused by the IgM M-protein, a large molecule that makes the blood more 
viscous. This may give rise to symptoms including headache, blurring of vision, vertigo, 
severe bleedings, thrombosis, and confusion.29  Peripheral neuropathy is seen in about 
20% of the patients as an autoimmune effect of the M-protein; other autoimmune 
symptoms include vasculitis, cryoglobulinemia, and hemolytic anemia.  
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1.2.3 Treatment and prognosis 
WM is a chronic disease and no curative treatment is available. However, overall survival 
has improved significantly during the last 30 years probably due to new treatment 
strategies.30 Negative prognostic factors are high age at diagnosis, anemia, 
thrombocytopenia, high levels of M-protein, and signs of renal failure. In patients with 
two risk factors the overall 5-year survival is still almost 70%.29 Only symptomatic 
patients should be treated. If there are signs of hyperviscosity, plasma exchange should 
always be considered. The standard primary treatment includes the anti-CD20 
monoclonal rituximab, most often in combination with cyclophosphamide and high-
dose steroids. Novel agents such as bendamustin and bortezomib can be added.29, 31 
ASCT is recommended for younger patients who do not respond to the first line 
treatment or relapse quickly.29  
1.3 Monoclonal gammopathy of undetermined 
significance (MGUS) 
The prevalence of MGUS in the population above 50 years of age is around 3%, and 
rises with increasing age. The condition is more common in males than in females.32 
There is evidence of a familial predisposition for MGUS and other lymphoproliferative 
or plasma cell disorders.33 An increased incidence has also been described among certain 
groups of immunocompromised patients, for example HIV-positive individuals and 
renal transplant recipients, and as a consequence of environmental factors such as 
occupational exposure to pesticides and petroleum products.32  
Patients with MGUS have a 25-fold increased risk of developing multiple myeloma, and 
a 46-fold increased risk of WM.34 Due to the potential of malignant transformation, 
MGUS patients need life-long follow-up with regular controls of their serum M-protein 
levels and clinical examinations. 
1.3.1 Definition 
A diagnosis of MGUS requires a serum M-protein concentration of less than 30 g/L,    
< 10% clonal plasma cells in the bone marrow, and no end-organ damage (i.e., no 
hypercalcemia, renal insufficiency, anemia, or osteolytic bone lesions).17 Around 15% of 
MGUS cases have a lymphoplasmacytic cell clone in the bone marrow and secrete M-
protein of IgM-type; the remaining 85% are of clonal plasma cell origin and secrete IgG 
or IgA M-protein.35 
1.3.2 Clinical features 
MGUS is commonly diagnosed during a medical examination for another cause, 
typically the finding of an elevated erythrocyte sedimentation rate or an abnormal serum 
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electrophoresis. Although MGUS is per definition an asymptomatic disorder there is 
evidence of increased co-morbidity regarding conditions such as skeletal disease 
(osteoporosis and fractures of hip and vertebrae), polyneuropathy, thromboembolism, 
dermatologic conditions, and bacterial as well as viral infections.1, 6, 36, 37 
1.3.3 Prognosis 
Patients with MGUS have an average annual risk of progression to multiple myeloma, 
Waldenstrom’s macroglobulinemia and other lymphoproliferative diseases of 1%. This 
risk remains even after 25 years of a stable gammopathy. However, the probability of 
progression is highly heterogeneous, and the majority of MGUS patients will never 
develop a lymphoproliferative malignancy.34 Rajkumar et al. defined three risk criteria for 
malignant transformation; a serum M-protein of ≥ 15 g/L, IgA or IgM MGUS, and an 
abnormal serum free light chain (FLC;  and ) ratio. Patients with all three risk factors 
had a risk of progression of 58% at 20 years from diagnosis while only 5% of patients 
without risk factors progressed during the same time period.38  
Kristinsson et al. found a poorer survival among MGUS patients than in the general 
population, specifically among elderly patients.39 The excess mortality in MGUS was not 
only due to progression to hematological malignancy. Patients with a diagnosis of 
MGUS also had a higher risk of dying from bacterial infections (hazard ratio [HR] = 
3.4), myeloid malignancies, heart disease, and liver and kidney diseases. Younger patients 
more often died from lymphoproliferative diseases while cardiovascular diseases 
dominated among the elderly.39 
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1.4 Infectious defense 
The human defense against infection can be divided into three arms: Functional barriers, 
innate immunity, and acquired or adaptive immunity. Barriers protecting against 
infection can be chemical, such as the hydrochloric acid in the stomach and lysozyme in 
the saliva, and mechanical such as the mucus layer covering the respiratory and gut 
epithelium. The innate and acquired immune systems consist of cells and molecules that 
recognize and react upon danger signals in the form of foreign pathogens or injured 
tissue. The cells involved are mainly white blood cells (neutrophilic and eosinophilic 
granulocytes, monocytes, basophilic granulocytes, mast cells, B- and T lymphocytes, and 
natural killer cells) derived from multipotential hematopoietic stem cells in the bone 
marrow. The hematopoiesis is summarized in Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The normal hematopoiesis in adults. Reprinted with permission of OpenStax.40 The figure may Figure 3.
be downloaded for free at http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-3ef2482e3e22@6.27. 
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1.4.1 Innate immunity 
The innate immune system is present in the host at birth and offers an immediate 
response to foreign antigens through an inflammatory process.  
This system recognizes a limited number of highly conserved structures that are 
common to different microbes, for example lipopolysaccharide and peptidoglycan 
present on bacteria, and viral RNA, but also endogenous danger elements in the form of 
injured or dead tissue. The microbial molecules are referred to as pathogen-associated 
molecular patterns (PAMPs), endogenous trigger molecules as danger-associated 
molecular patterns (DAMPs).41, 42 The system is activated through pattern recognition 
receptors (PRRs).41 These may be secreted, for example C-reactive protein (CRP) and 
mannose-binding lectin (MBL), which bind to bacteria and may activate the complement 
system.43 Other PRRs are bound to the surface of immune cells or are intracellular. The 
most well-known are the toll-like receptors (TLRs) which include surface as well as 
intracellular receptors that bind to bacterial components and viral RNA. The receptors 
signal via adaptor molecules, for example MyD88 which activates MAP kinases and the 
transcription factor NFB that induce the production of cytokines such as interleukin-1 
(IL-1), tumor necrosis factor (TNF), and IL-6. Soluble mediators including cytokines, 
prostaglandins, and oxygen radicals that are released as part of the inflammatory process 
play a key role in the recruiting of other immune cells as well as triggering of the 
adaptive immune system.  
Cells involved in innate immunity include the neutrophils, eosinophils and basophils, 
monocytes, macrophages, dendritic cells, mast cells, and the natural killer (NK) cells.44  
Opposite to the adaptive immune system, innate immunity has no immunologic 
memory. 
PHAGOCYTOSIS AND OPSONIZATION 
There are several mechanisms by which the innate immune system rids the body of 
invaders, including phagocytosis, complement activation, and inhibition of virus 
replication.  
Phagocytosis is, together with the complement system, the most important anti-bacterial 
systems in the human. It is exerted predominantly by macrophages and neutrophilic 
granulocytes. After adhesion to the phagocyte cell surface, the foreign body is engulfed 
in a vesicle, a phagosome, in the cytoplasm of the cell to which toxic substances such as 
lysozyme and defensins are recruited and eventually kill the intruder. The production of 
toxic oxygen radicals is crucial in the killing process.44 
Macrophages can be activated by direct contact with the microbe, but also by the 
binding of a microbe to a PRR. Opsonization is a way of facilitating phagocytosis, 
particularly of encapsulated organisms. The foreign body is covered by opsonins, either 
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antibodies of the IgG isotype or by C3b complement fragments, which in their turn 
bind to specific receptors (Fc, C3b receptors) on the phagocytosing cell (macrophages, 
neutrophils). Opsonization also enables  phagocytes  to recognize pathogens that do not 
express PAMPs, for example viruses.45 Pneumococci are difficult targets due to the 
polysaccharide capsule that surrounds the bacteria and protects against phagocytosis.46 
In this case, opsonization with complement factors (the classical pathway; see below) 
and antibodies is required for effective killing. Conversely, patients with antibody or 
complement deficiencies are at increased risk of developing severe pneumococcal 
infections.47 
Dendritic cells also have phagocytic capacity. However, their main function is antigen-
presentation whereby they act as a bridge to the adaptive immune system. NK cells kill 
their targets, typically virus-infected or  malignant cells, through induction of apoptosis 
or directly by secretion of cytotoxic substances such as perforins and granzymes without  
previous antigen presentation.48 
COMPLEMENT 
The complement system is a series of plasma proteins that plays an essential role in 
innate immunity by facilitating phagocytosis, attracting leukocytes, and directly lysing 
microbes. Many of the complement factors are proteases, which cleave and activate the 
next member of the system. The central process is the cleavage of factor C3 into C3a 
and C3b, after which the C3b fragment can opsonize foreign bodies, thereby 
dramatically increasing phagocytosis. 
There are three different pathways by which the complement system is activated: the 
classical pathway, the alternate pathway, and the lectin-binding pathway. The lectin-
binding pathway uses the complement factor mannose-binding lectin (MBL) that binds 
to carbohydrate surface structures of bacteria and fungi. This results in the activation of 
an enzyme, MBL-associated serine protease (MASP), which cleaves factors C4 and C2. 
An enzyme complex, C4b2a, is created, which in turn cleaves factor C3.45 
The classical pathway is activated by antibodies bound to an antigen, for example 
bacteria. Antibodies of the IgG and IgM isotypes have binding sites for the complement 
factor C1q. When at least two arms of immunoglobulins are cross-linked by C1q 
molecules, the C1 complex containing C1q, C1r and C1s is activated. C1s cleaves factors 
C4 and C2, and as in the lectin-binding pathway, the C4b2a enzyme complex cleaves 
factor C3.45 Since the IgM molecule has many binding sites for complement it is a much 
more potent activator of the complement system than IgG. The classical pathway is 
essential for the phagocytosis of encapsulated bacteria such as pneumococci. 
The alternate pathway is a reinforcing system of the other two pathways, and becomes 
activated as soon as C3b has bound to a surface. It may then bind factor B, which is 
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further cleaved by factor D. The remaining complex, C3bBb, converts C3 into C3a and 
C3b. The C3bBb convertase is very short-lived but is stabilized by binding to properdin, 
which prolongs the convertase’s half-life 5- to 10-fold allowing for the production of 
larger amounts of the C3b opsonin.45   
 
 
 
 
 
 
 
 
 
 
 
 
 The complement cascade. Reprinted with permission of Elsevier.44 Figure 4.
The direct cell lysing potential of the complement system is effectuated by the 
“membrane attack complex”, which is composed of the terminal complement 
components C5-C9. Its formation is initiated by the cleavage of factor C5 by the binding 
of C3b and either of the classical or alternative pathways’ C3 convertases. Factors C5-C8 
create an anchor site for the C9 molecules, which form the actual attack complex that 
can penetrate and lyse gram-negative bacteria, and also inactivate viruses.44 
The complement fragments C3a-C5a which are released during activation of the 
complement system are also called anaphylatoxins. C3a causes degranulation of mast 
cells with the release of histamine, which increases the permeability of blood vessels and 
allows for the spread of plasma proteins into the tissue.45 C5a induces chemotaxis of 
neutrophils and monocytes, attracting them to areas of inflammation. 
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NATURAL IGM  
IgM antibodies can be subdivided into natural and immune IgM. The latter are antigen-
specific and produced upon exposure to specific pathogens (see below). In contrast, 
natural IgM antibodies are poly-reactive and can bind to a large number of conserved 
epitopes shared by diverse microorganisms. It acts as  part of the first line defense 
against infections, and its receptor has been found on all lymphoid and myeloid cells but 
with the highest levels on B lymphocytes.49 This low-affinity antibody type does not 
require antigen presentation and is already present at birth. 
Natural IgM has been shown to protect against infection, to clear apoptotic and dying 
cells from the circulation, to regulate inflammation by binding to lymphocytes and 
inhibiting cell division or activation, but also to induce autoimmune disease.49 Natural 
IgM has an important role in the early defense against pneumococci and other 
encapsulated bacteria. It has been shown to contribute to the protection against invasive 
disease by clearing bacteria from the circulation and delocalizing them to the marginal 
zone of the spleen.50 Natural IgM is also capable of activating the classical complement 
pathway.51  
1.4.2 Acquired immunity 
In contrast to innate immunity, the acquired or adaptive immune system is not pre-
formed at birth but educated upon encounter with antigens. It is also called specific 
immunity since the participating cells, the T and the B lymphocytes possess unique 
receptors on their cell membranes that recognize and distinguish individual antigenic 
epitopes, specific for each individual lymphocyte. The system has an almost unlimited 
capability of detecting new structures. The key feature of the acquired immune system is 
its memory function. A proportion of the lymphocytes that have reacted to an 
encountered antigen will develop into memory cells. These remain inactive until the next 
time the individual is exposed to the same antigen, when they provide a much faster and 
stronger response than at the primary encounter (a few hours vs. 1-2 weeks). 
T CELLS 
T cells recognize antigenic epitopes via a specific T cell receptor. Pre-T cells are formed 
in the bone marrow and migrate to the thymus, where T cell receptor rearrangement 
occurs and the cells develop into mature T lymphocytes; T cells reactive to self-antigens 
are sorted out. 
Antigens are presented to the T lymphocytes by MHC (major histocompatibility 
complex) molecules. MHC class I can be found on most cell types in the human body 
while MHC class II molecules are foremost present on specific antigen-presenting cells 
that are part of the innate immune system, such as macrophages and dendritic cells. The 
T cells that attach to MHC class I have a CD8 co-receptor on their surface while those 
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that bind to MHC class II have a CD4 co-receptor. The CD4+ T cells secrete cytokines 
and chemokines that activate and recruit other immune cells such as macrophages, B 
lymphocytes, and cytotoxic (CD8+) T lymphocytes.52 The CD8+ cells mainly act by 
secreting lytic proteins that destroy host cells infected by microbes.53 
Upon antigenic stimulation, naïve CD4+ T cells differentiate into different subsets of T 
helper (Th) cells or regulatory T cells (Tregs), see Figure 5. Th1 T cells secrete 
interferon-(IFN-) that activates macrophages and dendritic cells and are important in 
the defense against intracellular pathogens such as Mycobacterium tuberculosis.54 Th2 cells 
are maybe best known for their role in allergic diseases but are also active in the defense 
against parasite infections and in the activation of B lymphocytes, while theTh17 cells 
seem to have critical functions in the clearance of extracellular bacteria and fungi.52 
Tregs (CD4+CD25+) are crucial players in the suppression of auto-reactive T cells as 
well as in protecting the host against excessive immune responses towards foreign 
antigens.55 
Naïve CD8+ T cells differentiate into cytotoxic T lymphocytes upon antigenic 
stimulation. Their lytic function is mediated by perforin release and the Fas-pathway, 
and is essential in the defense against viral infections since lysis of infected cells halts 
viral replication.53  
 
 
 
 
 
 
 T cell differentiation. Figure 5.
 
B CELLS 
The B cell recognizes its antigen by a membrane-bound antibody, the B cell receptor. 
Once a naïve B cell has encountered its specific antigenic epitope, it becomes activated 
and develops either into a plasma cell, which produces and secretes large amounts of the 
same type of antibody as its B cell receptor, or a memory B cell of the same specificity. 
The rearrangement of the B cell receptor occurs in the bone marrow. Activated B     
Naïve T cell
CD8+ T cell
Cytotoxic T cell
CD4+ T cell
Treg Th1 Th2 Th17
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(and T) lymphocytes primarily reside in the secondary lymphoid organs, the lymph 
glands and the spleen, which provide a milieu designed to facilitate the encounter with 
their cognate antigens. Eighty percent of the naïve B cells never locate their specific 
antigen and die about a week after leaving the bone marrow.56 
The activation of B cells also requires the presence of T helper cells specific for the 
same antigen. In order to attract and activate these T cells the B lymphocytes can act as 
antigen-presenting cells by upregulating MHC class II molecules that present peptides of 
the antigen bound to the B cell receptor. The activated T helper cell secretes cytokines 
essential for  B cell activation, typically IL-4, IL-6, and IL-10.45 The process is enhanced 
by the expression of co-receptors on the B cell, for example CD40, which binds the 
CD40 ligand (CD40L) on the T helper cell. This binding promotes the switch of 
antibody isotypes from IgM to IgG, IgA, and IgE.57  
Some antigens, such as the polysaccharide capsules of pneumococci and Haemophilus 
influenzae type b, can provide T cell-independent B cell activation. These antigens are 
typically large molecules with repetitive carbohydrate motifs that interact with multiple 
IgM B cell receptors simultaneously and induce a strong stimulating signal to the B cell. 
B cells expressing membrane receptors specific for such T cell-independent antigens  
reside in the marginal zone of the spleen and are able to provide a quick antibody 
response to blood-borne pathogens.45 
ANTIBODIES 
Antibodies are serum proteins that aid the host in the clearance of pathogens. They do 
not have a killing capacity of their own but exert their function by blocking, or 
neutralizing the microbe or toxin thereby preventing it to attach to its target cells, by 
facilitation of phagocytosis through opsonization, and by complement activation.45  
The antibody consists of two identical heavy chains and two identical light chains. The 
chains have variable (V) and constant (C) domains. There are five variations of the 
constant domains of the heavy chains, which form the basis for the five 
immunoglobulin classes produced (IgM, IgG, IgA, IgE, IgD). Two classes of light 
chains exist,  (kappa) and(lambda). The highly variable antigen-binding end of the 
antibody is called the Fab region, the constant “tail”, which binds the effector cells, is 
named the Fc region.  
The different immunoglobulin classes have different functions and sites where they are 
likely to reside. IgM is the largest molecule and consists of five antibody units joined by 
a J chain. It can bind at least five antigens simultaneously thus providing effective 
blocking and aggregation of pathogens. The Fc region of IgM and IgG has a binding 
site for complement factor C1; IgM is the most potent complement activator.45  
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 Schematic design of an antibody and the formation of IgM. Fab, fragment antigen binding; Fc, Figure 6.
fragment crystallizable. 
IgG is the dominating isotype in serum and the only antibody class that can cross the 
placenta.58 Four subclasses of IgG, IgG1-4, exist in humans. IgG1 and IgG3 have high 
complement activating capacity, while IgG2 fixes complement poorly and IgG4 not at 
all. IgG antibodies to protein antigens are typically IgG1 and IgG3, while 
polysaccharides tend to give rise to an IgG2 response.45, 59, 60 IgG2 subclass deficiency 
may therefore cause an increased susceptibility to encapsulated bacteria such as 
pneumococci.61 
IgA exists in a monomeric form in serum and as secretory IgA on mucosal surfaces. 
Dimeric IgA is secreted by submucosal plasma cells and binds to “secretory 
component” on the basolateral side of epithelial cells. This complex is released into 
mucosal secretions, and the secretory component protects the antibody from cleavage 
by enzymes and gastric acid. IgA has poor capacity of inducing inflammation but 
effectively blocks the binding of bacteria, viruses, and toxins to target cells on mucosal 
surfaces.45 
IgE binds to Fc receptors on mast cells and is responsible for allergic and anaphylactic 
reactions. IgD is expressed on the B cell membrane early during B cell differentiation 
and only small amounts are found in the serum; its function is largely unknown. 
At the primary encounter with a pathogen, mainly IgM antibodies are produced. 
However, as the immune response progresses, some B cells switch to the other Ig 
classes (isotype switch). In parallel, the binding affinity of the antibody for the antigen 
increases by a process named somatic hypermutation. These processes occur in the 
germinal centers of lymph nodes and the spleen. Antibody affinity refers to the strength 
of the specific antibody-antigen binding. Antibody avidity is a wider concept influenced 
both by the antibody affinity and the contribution of multiple binding sites on the same 
antibody.  
antigen-binding
site
light chain
heavy chain
Fab
Fc
IgM
IgE
IgD
IgM
IgG
IgA
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If a primary B cell response develops successfully, it is expected that upon renewed 
exposure to the same antigen, the secondary response will feature an IgM response of 
the same magnitude and duration, with a much more rapid and intense high-affinity IgG 
(or A, E) response.  
1.4.3 B cell memory 
Humoral immunity relies on B cell memory function, which is maintained by two 
different kinds of cells: the long-lived plasma cells and the memory B cells. The long-
lived plasma cells reside in the bone marrow and may survive for months and years, in 
contrast to the short-lived plasma cells which have half-lives of only a few days.62 The 
long-lived plasma cells have down-regulated their surface antigen receptors and can thus 
not be stimulated by antigen re-exposure. Instead they provide a constant release of 
high-affinity serum antibodies, which offers a first-line defense upon renewed encounter 
with known microbial antigens.63  
Memory B cells are responsible for the rapid increase of specific antibodies at re-
exposure to a previously encountered antigen by differentiation into short-lived plasma 
cells. The memory B cells are possibly also involved in replenishing the pool of long-
lived plasma cells in the absence of pathogens.64 Most memory B cells are isotype-
switched and produce protective antibodies of mainly the IgG isotype. Another 
population, called IgM memory B cells, has been identified in the peripheral blood. 
These cells may be generated independently of germinal centers and have been shown 
to undergo somatic hypermutation but not isotype switch. They are involved in antibody 
production against T cell-independent antigens only, for example pneumococcal 
capsular polysaccharides.65 
1.4.4 Pneumococcal immunity 
Phagocytosis of bacteria opsonized by complement or antibodies is the classical host 
defense mechanism against pneumococci. Its importance is illustrated by the increased 
risk of pneumococcal infection seen in patients with complement or antibody 
deficiencies. Complement activation is primarily induced by the classical pathway and is 
enhanced by natural IgM.47 C-reactive protein (CRP) is a soluble PRR of significance in 
the defense against pneumococci. Its name derives from the fact that it binds to 
pneumococcal cell wall constituent C-polysaccharide (CPS), whereupon complement is 
activated. Several TLRs are activated by pneumococci, for example TLR2 and TLR4, 
and deficiencies in their respective downstream intracellular signaling systems have been 
associated with an increased risk of pneumococcal infections.47 B cells are crucial in the 
defense against pneumococcal infections. Specific anti-capsular antibodies are produced 
within a week after the onset of infection and induce an effective opsonophagocytic 
clearance of the bacteria.45 They have also been shown to contribute to resistance 
against pneumococcal colonization.66 Non-capsular antibodies directed towards various 
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components of the pneumococcal cell wall, such as CPS, are thought to contribute to 
this as well as to protection against invasive disease.66, 67 In parallel, it is believed that 
CD4+ T cells play an important role in the acquired immunity against pneumococci, 
which may be illustrated by the highly increased risk of pneumococcal infection in 
untreated HIV patients with severe CD4+ T cell deficiency. Pneumococcus-specific 
CD4+ TH17 cells have been proposed as effector cells involved in reducing the 
duration of pneumococcal carriage and possibly also in preventing non-invasive 
pneumococcal disease.67          
1.4.5 Vaccination 
Vaccines based on plain polysaccharide antigens act in a T cell-independent manner, 
since T cells are programmed only to recognize linear protein fragments, peptides. 
Because of the lack of T cell secondary signals, B cells producing antibodies to 
polysaccharides cannot generate the classical immunologic memory emanating from 
IgG-switched memory B cells with high antibody affinity. The effect of polysaccharide 
vaccines is typically short-lived and cannot be boosted. Polysaccharides activate B cells 
of the splenic marginal zone.68 These cells do not mature until the second year of life, 
and polysaccharide vaccines are thus poorly immunogenic in infants. The specific subset 
of IgM memory B cells has been identified as a potential circulating counterpart of 
marginal zone B cells,69, 70 and patients with decreased or low levels of this B cell type, 
including splenectomized persons, infants < 2 years of age, and the elderly respond 
poorly to polysaccharide vaccines.71 
To overcome the inherent polysaccharide vaccine resistance of infants, conjugated 
polysaccharide vaccines have been developed. These vaccines contain a protein carrier, 
for example tetanus or diphtheria toxoid, that is covalently linked to the polysaccharide 
antigen and by which a T-dependent vaccine response can be induced. The 
polysaccharide-specific B cells internalize the conjugate and act as their own antigen-
presenting cells by displaying peptides of the protein conjugate on their own surface 
MHC class II molecules. T cells specific for the conjugate provide help for the B cells to 
enable isotype switching and formation of memory B cells. In contrast to 
polysaccharides, protein antigens typically activate B cells in the lymphoid follicles of the 
spleen or lymph nodes.68                                                                                                              
1.4.6 Immunosenescence 
Bacterial and viral infections, such as urinary tract infections, pneumonia, sepsis, 
influenza and herpes zoster are both more common and more severe among the elderly 
(> 65 years of age).72 This has many reasons, including age-associated physiological and 
anatomical changes, co-morbidities, malnutrition, but also alterations of the immune 
system with a decreased capacity to eliminate infections. The latter phenomenon is 
referred to as immunosenescence.  
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One theory behind the immunosenescence is that chronic infections, typically  with 
persistent viruses such as cytomegalovirus (CMV), cause an exhaustion of the immune 
system by recurring reactivations throughout life and a gradual decrement in the T cell 
repertoire.73 In parallel, elevated levels of pro-inflammatory molecules such as 
interleukin 6 (IL-6), tumor necrosis factor (TNF) and CRP have been described in 
elderly populations. This causes a chronic low-grade inflammatory state, “inflamm-
aging”, which is associated with atherosclerosis and other age-related conditions and 
may augment the tissue-damaging effect of infectious agents in the elderly.73-75  
Immunosenescence affects both acquired and innate immunity. Regarding the innate 
immune system, these changes have been shown to include cells as well as soluble 
mediators such as cytokines, chemokines and reactive oxygen species. 74 Age-related 
dysfunctions of neutrophils include reduced chemotaxis, phagocytosis, production of 
free radicals, and increased susceptibility to apoptosis.75  Antigen-presenting cells such as 
dendritic cells and monocytes/macrophages have decreased capacity to ingest and 
present antigens, resulting in reduced T cell activation and proliferation.73, 74 
Macrophage functions may also be compromised with decreased phagocytic capacity 
and killing of bacteria through oxidative burst.76 Increased numbers of NK cells feature  
in the elderly,77 possibly as a compensatory mechanism for decreased cytolytic 
capacity.74, 76 
A fundamental change in immunosenescence is the involution of the thymus. This 
causes a decreasing output of naïve T cells and consequently, a restricted diversity of 
CD4+ and CD8+ T cells with a reduced capacity of the host to respond to new 
antigens.74 Instead, there is a shift towards accumulation of antigen-experienced memory 
and effector T lymphocytes. In the aging individual, these T cells may express lower 
levels of co-stimulatory molecules such as CD28 and CD40L, and reduced production 
of the growth factor IL-2, the net result being a reduced capacity of CD4+ T cells to 
stimulate B cell proliferation and antibody production. The repertoire of CD8+ T cells 
is often dominated by clones of effector cells, typically CMV-specific.78 The thymus 
involution also reduces the output of T regulatory cells, which may contribute to 
inflammation and autoimmunity.79 
Similar to the T cell line, naïve B cells decline in number with aging while primed 
memory cells seem to maintain their levels.73, 74 Clonal expansions of memory B cells 
with a decreased susceptibility to apoptosis may limit the diversity of the B cell 
repertoire, and reduced numbers of plasma cells in elderly have been described.80 Also, 
IgM memory B cells decrease with age, which affects the defense against encapsulated 
bacteria.71, 73 Although total serum immunoglobulin levels seem to be stable during 
aging, fewer antigen-specific antibodies are produced while autoantibody titers 
increase.77, 81 In parallel, antibodies produced in old age are of lower affinity74, 81 The 
interplay with other immune cells needed for B cell activation is impaired not only by T 
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cell changes (see above) but also as a result of decreased co-stimulatory molecules on B 
cells such as CD40 and CD27.74 
Humoral and cellular immunosenescence explains the poor immunogenicity and efficacy 
of vaccination in the elderly. Studies on immune responses to influenza vaccine have 
shown a 70-90% efficacy in adults < 65 years of age while the level of protection in the 
age group of > 65 years was at most 50%.82, 83 Pneumococcal vaccination with a 
polysaccharide vaccine is  protective against invasive pneumococcal disease in adults,84 
but the effectiveness in an elderly population is debated.84, 85 In a post-hoc analysis of 
the Dutch CAPiTA (Community-Acquired Pneumonia Immunization Trial in Adults) 
study involving > 80.000 non-immunocompromised individuals > 65 years of age 86 the 
predicted efficacy of a conjugated pneumococcal vaccine in preventing pneumonia and 
invasive pneumococcal disease was 65% in 65-year old subjects, 40% in 75-year old 
subjects.87 Studies of the superiority of any of the vaccine types in the elderly have been 
inconclusive.88-90 In parallel, naturally acquired antibodies against pneumococci decrease 
with age.88, 91 
1.4.7 Immunodeficiency in B cell disorders 
Immunodeficiency in B cell malignancies affects various parts of the immune system. It 
involves dysfunction and abnormalities of B cells, T cells, dendritic cells, and NK cells 
as well as changes on a molecular level with increased levels of cytokines and other 
immunologically active compounds that promote the growth of the malignancy and 
create an immunosuppressive microenvironment. 
Polyclonal hypogammaglobulinemia is the classical marker of immune deficiency in B 
cell malignancies and is seen in most cases of multiple myeloma.92, 93 A study of 
untreated WM patients revealed low levels of IgA, IgG, or both in 63%, 58%, and 49% 
of the patients, respectively.94 The prevalence of hypogammaglobulinemia in MGUS is 
lower but still at a level of 25-30%.95, 96  
The hypogammaglobulinemia in myeloma has been shown to reflect a suppression of 
CD19+ B lymphocytes, which correlates inversely with disease stage.92, 97 Reduced levels 
of B cells have also been demonstrated in WM and MGUS.98, 99 When MGUS 
progresses into multiple myeloma, clonal plasma cells (CD19-) successively replace 
normal plasma cells (CD19+). Olteanu et al. found that a mean of 27% of total bone 
marrow plasma cells in MGUS patients were normal compared to only 3% in myeloma 
patients,100 highlighting the deteriorated B cell memory due to reduction of healthy long-
lived plasma cells in multiple myeloma. When comparing B cells in patients with 
myeloma, WM, and MGUS Pilarski et al. found an enriched proportion of B cells auto-
reactive to polyclonal Ig in multiple myeloma, but not in WM or MGUS. In contrast to 
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myeloma, levels and function of tetanus-specific B cells were normal in WM and in most 
MGUS patients.99, 101 
The T cell repertoire in multiple myeloma, WM and MGUS is characterized by a 
decreased ratio of CD4+/CD8+ cells, which has been related to reduced numbers of 
CD4+ cells as well as to a rise in CD8+ cells.98, 99, 102 Also, an imbalance of the CD4+ T 
helper cells has been shown in myeloma with an increased ratio of Th1/Th2 cells.102 As 
in normal immunosenescence, the T cell diversity is reduced and the remaining clones 
of CD4+ and CD8+ T cells are expanded; however, this is more pronounced in patients 
with a B cell malignancy97, 103 Impaired functional T cell responses are common. 
Maecker et al. compared the CD8+ T cell response to influenza A and Epstein-Barr 
virus in myeloma patients and healthy controls, and found that less than 30% of the 
myeloma patients but 67% of the controls responded with increased numbers of virus-
specific T cells after stimulation.104 Studies on regulatory T cells (Tregs) in myeloma and 
MGUS have had inconsistent results, but a majority have shown increased numbers of 
Tregs in myeloma with a correlation to disease activity.93 
Suppression of dendritic cells (DCs) has been described in MGUS but much more 
markedly in multiple myeloma, where a reduced antigen-presenting capacity and ability 
to induce T cell proliferation has also been shown.93, 105 NK cells are increased in MGUS 
and in the early stages of multiple myeloma.93, 98 They have an important role in lysis of 
malignant cells; however, this anti-myeloma effect decreases with progression of the 
disease through the down-regulation of activating receptors on NK cells and of reduced 
numbers of NK cell receptors on myeloma tumor cells.93, 97  
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1.5 Infections in B cell disorders 
Infectious complications are a leading cause of morbidity and mortality in patients with 
multiple myeloma.4, 106 Increased susceptibility to infection is also seen in Waldenstrom’s 
macroglobulinemia and MGUS5, 6 but the incidence of infections is lower than in 
multiple myeloma.107, 108 Besides the disease-induced immunodeficiency, age-dependent 
decline of immune functions as well as co-morbidities and immobility increase the risk 
of infections in this mainly elderly population of patients.73, 109 Other factors that 
contribute to the vulnerability to infection include treatment-induced immuno-
suppression, mucosal damage after chemotherapy and stem cell transplantation, 
hyperglycemia due to high doses of corticosteroids, transfusional iron overload, and in 
the case of multiple myeloma, renal failure and respiratory depression caused by 
fractures of thoracic vertebrae and use of opiates.106  
MULTIPLE MYELOMA  
A recent Swedish population-based study of more than 9000 multiple myeloma patients 
revealed a 7-fold increased risk of contracting any infection compared to matched 
controls,110 which is in accordance with older literature.107, 111 The incidence of a number 
of bacterial infections was significantly increased, foremost meningitis (HR = 16.6), 
sepsis (HR = 15.6) and pneumonia (HR = 7.7), but also herpes zoster (HR = 14.8) and 
influenza (HR = 6.1).110 
Bacterial infections, typically pneumonia and sepsis, are predominant in multiple 
myeloma although viral infections appear to be on the rise.112 Encapsulated bacteria 
such as Streptococcus pneumoniae and Haemophilus influenzae are classical pathogens, and the 
increased risk of infection is related to the polyclonal hypogammaglobulinemia seen in a 
majority of myeloma patients.106 However, the etiologic spectrum has shifted and gram-
negative bacteria, typically Escherichia coli, are now the most common pathogens 
alongside with Staphylococcus aureus and S. pneumoniae. 4, 18, 112-114 Infections caused by 
encapsulated bacteria are commonly seen early in the disease while gram-negative and S 
aureus infections have an increasing incidence later on during the disease and 
predominate in patients with renal failure.4, 18 
The risk of infection in multiple myeloma is closely related to disease activity and 
treatment. The highest risk is seen within the first months after diagnosis.4, 110, 115 
Augustson et al. showed that 45% of early deaths (< 60 days from diagnosis; 10% of all 
deaths) were attributable to infections.115 A 4-fold higher risk of infection has been 
found in relapsed/progressive disease compared to plateau-phase myeloma.19 A recent 
study by Teh et al. described a bimodal distribution of bacterial and viral infections with 
a late rise in incidence at around 70 and 52 months, respectively. This coincides with 
end-stage progressive disease combined with cumulative immunosuppression following 
multiple treatment lines.112 
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 Risk periods for infection in multiple myeloma. ASCT, autologous stem cell transplantation. Figure 7.
Reprinted with permission of Wiley and sons.112 
WALDENSTROM’S MACROGLOBULINEMIA 
The literature on infectious complications in WM is sparse and consists mainly of case 
reports of severe infections, foremost bacterial, while systematic reviews are missing. In 
one retrospective study of clinical features and outcome of 217 patients with a diagnosis 
of WM, infection was the second most common cause of death next to development of 
a second malignancy. Of the 52 deaths during the study, 10 (19%) were due to 
infections, predominantly sepsis and pneumonia.5 In a study from 1963, Fahey et al. 
compared infections in myeloma and WM patients and found a 3-fold lower incidence 
in WM patients but similar types of infections.107 
MGUS 
Infections in MGUS have been more studied than in WM. In a recent Swedish 
population-based study, MGUS patients had a 2-fold risk of developing any infection 
compared to controls.6 There was an increased risk of pneumonia, septicemia, 
osteomyelitis, pyelonephritis, cellulitis, endocarditis, and meningitis, as well as of 
influenza and herpes zoster with HRs between 1.7 and 3.2. M-protein levels of > 25 g/L 
were associated with a higher risk of infection but the risk was still elevated in patients 
with an M-protein of < 5 g/L. Increased incidence of bacteremia in MGUS patients has 
previously been described in a Danish study with S. aureus and E. coli as the most 
common causative agents.116 Bida et al. found an association of MGUS with respiratory 
bacterial infections, bacterial peritonitis, and mycobacterial infections.36 Also, there is 
evidence of an excess mortality due to infections in patients with MGUS.39, 96 
Kristinsson et al. showed that patients with MGUS have a 3.4-fold risk of succumbing to 
a bacterial infection compared to controls.39  
 22 
1.5.1 Infections related to treatment 
Treatment-induced infections are a major concern in multiple myeloma. Neutropenia 
after treatment by classical combinations of chemotherapy and corticosteroids such as 
melphalan and prednisone typically causes bacterial infections. However, the 
introduction of more intensive treatment and addition of immunomodulatory drugs has 
led to prolonged survival but also to increased immunosuppression, and the number and 
spectrum of infections has widened.106, 110  
Dexamethasone, especially in high doses, enhances the risk of infections caused by 
depression of cell-mediated immunity, such as Candida, herpes simplex virus (HSV) and 
varicella zoster virus (VZV) infections.93, 106  
Thalidomide and lenalidomide are anti-angiogenic drugs with stimulatory effects on T 
cells and NK cells.117 However, these agents may cause higher numbers of severe 
infections compared to older treatment regimens.118, 119 Myeloma patients with relapsed 
disease treated with lenalidomide and high-dose steroids had higher rates of neutropenia 
and a doubled risk of severe infection compared to patients on dexamethasone alone.119 
Bortezomib has suppressive effects on T cells and is associated with increased risk of 
HSV and VZV/herpes zoster infections.106, 120  
High-dose chemotherapy before ASCT is associated with severe neutropenia and a high 
risk of bacterial infections.106 Microbiologically confirmed infections afflict about 30% 
of newly transplanted myeloma patients.121, 122 The transplant procedure causes 
prolonged suppression of cell-mediated immunity, and opportunistic infections with 
CMV, HSV, VZV, Pneumocystis jiroveci, Candida, and moulds are seen.92, 106, 123 Also, 
respiratory virus (RV) infections such as influenza and respiratory syncytial virus have a 
high incidence in stem cell transplanted patients as well as in patients on 
immunomodulatory treatment and are associated with prolonged hospital stay and 
mortality.124-127 Lymphocytopenia is a commonly referred risk factor. Teh et al. found 
the highest incidence of RV infections in patients with progressive disease and in 
recipients of multiple lines of therapy.127 
Modern treatment of WM generally includes Rituximab, a monoclonal antibody directed 
towards CD20, which is expressed by all B cells except for plasma cells. The use of 
Rituximab as monotherapy in lymphomas and rheumatoid arthritis gives an incidence 
rate of infectious events of 30%.128 The infectious etiology includes bacterial, viral, and 
fungal infections, as well as opportunistic infections such as P. jiroveci pneumonia and 
reactivation of HSV, VZV and CMV.129 Since other treatment options in WM are 
similar to those in multiple myeloma, including immunomodulatory drugs and ASCT, 
the spectrum of infectious complications is similar. 
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1.5.2 Prevention of infection 
VACCINATION 
Vaccine responses are generally reduced in patients with B cell malignancies. 
Vaccination against influenza, S. pneumoniae, and H. influenzae type b (Hib) is 
recommended but the benefits are uncertain.106, 130 In a study by Robertson et al., only 
19% of myeloma patients developed protective antibody titers against influenza A of 
two strains and influenza B.131 Even poorer response rates were found in a Swedish 
study of patients with hematological malignancies including myeloma, and no effect of 
repeated vaccination was seen.132 Influenza vaccination of household members might be 
of greater importance for these patients.  
Initial studies of pneumococcal polysaccharide vaccines in multiple myeloma and WM 
patients during the 1980s showed suboptimal responses.133-135 This was later confirmed 
in a study of 42 myeloma patients who received the 23-valent pneumococcal 
polysaccharide vaccine (PPV), of whom 38% failed to produce any IgG response.19 
Also, low anti-pneumococcal titers predicted a higher risk of severe infection. Robertson 
et al. found low antibody titers in 61% of myeloma patients vaccinated with PPV, but a 
good serological response defined as a 4-fold antibody titer increase in 56% of the 
patients.131 The 7-valent conjugated pneumococcal vaccine (PCV7) has been evaluated 
in combination with PPV after ASCT in a small study of mainly multiple myeloma 
patients.136 A response rate of 33% was seen after 2 doses of PCV7, and of 78% against 
the PCV7 serotypes after the PPV booster.  
Current American guidelines for pneumococcal vaccination of immunocompromised 
patients including those with B cell malignancies recommend one dose of the 13-valent 
conjugated vaccine (PCV13) followed by one dose of PPV at least 2 months later.137 
The European guidelines for ASCT patients recommend three doses of PCV13 
followed by one dose of PPV; however, this recommendation is based on studies of 
allogeneic stem cell transplant recipients.132 Possible advantages and shortcomings of 
PCVs vs. PPV in immunocompromised patients are discussed in Chapter 1.7.3. 
In contrast to influenza and pneumococcal immunity, levels of Hib antibodies in 
myeloma patients have been found to be comparable to the general population, before 
as well as after vaccination, and the benefit of the vaccine has been questioned.131 Also, 
after the introduction of the Hib vaccine in childhood immunization programs the 
incidence of H. influenzae type b infections has decreased in all age groups and Hib has 
largely been replaced by other Haemophilus species.138 
The live vaccine against herpes zoster reactivation is contraindicated in immuno-
compromised patients including patients with B cell malignancies, but studies on 
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recombinant varicella vaccines in ASCT recipients are ongoing and might be a future 
alternative.139 
The timing of vaccination with regard to disease stage, treatment and transplantation is 
an important but largely unexplored research field. In a pilot study by Noonan et al. 
lenalidomide treatment of myeloma patients seemed to augment pneumococcal vaccine 
responses, indicating that IMiDs might work as vaccine adjuvants.140 After ASCT, a 
longer interval between transplantation and vaccination is generally associated with 
better vaccine responses,93 but this has to be balanced against the heightened risk of 
infections during this period of severe immunosuppression. Also, it has been shown that 
vaccinations against pneumococci and influenza given pre-transplant with a booster 
dose after transplantation have resulted in better responses.141, 142 Immunization has not 
been evaluated in MGUS patients. 
ANTIBIOTIC PROPHYLAXIS 
Due to the substantial risk of infections in patients with B cell malignancies, 
antimicrobial prophylaxis is recommended in several situations. Patients treated with 
high-dose steroids may be given prophylaxis against P. jiroveci, preferably with 
trimethoprim-sulfamethoxazole (TMP-SMX).15, 106, 143 This should also be considered in 
rituximab-based regimes in WM patients.29 Aciclovir prophylaxis is recommended for all 
patients on bortezomib-containing regimes.15, 29, 144 Antiviral as well as P. jiroveci 
prophylaxis is given routinely for 6 to 12 months after ASCT.  
Antibiotic prophylaxis with TMP-SMX during the first months of disease has previously 
been shown effective145 and could be considered according to guidelines.130, 146 
However, a recent study by Vesole et al. did not show a benefit of either TMP-SMX or 
ciprofloxacin vs. patients who were not given prophylaxis.147 Swedish myeloma 
guidelines recommend antibiotic prophylaxis in patients with recurrent bacterial 
infections.15 
INTRAVENOUS IMMUNOGLOBULIN 
One small randomized trial has evaluated the use of intravenous immunoglobulin (IVIg) 
in multiple myeloma and showed a significantly reduced risk of infections in the 
treatment arm.148 The patients were at a stable disease stage and did not receive 
antibiotic prophylaxis. Current guidelines for B cell malignancies and disorders 
recommend that IVIg should be reserved for patients with hypogammaglobulinemia and 
severe recurrent infections.15, 29, 130 Due to its high cost, a serum level of IgG of < 5g/L 
has been proposed for IVIg treatment.106 IVIg has also been investigated during and 
after ASCT but did not reduce infectious complications.126, 149, 150 
 25 
1.5.3 Treatment of infections 
Infections in patients with B cell malignancies, especially multiple myeloma, are very 
common but may be difficult to correctly diagnose. The spectrum of potential 
pathogens is wide, and manifestations of infection may be masked by severe suppression 
of cell-mediated immunity as well as neutropenia due to disease progression and 
treatment.106 Also, antimicrobial prophylaxis may complicate the diagnosis of infections. 
Patients with fever should be treated promptly with broad-spectrum antibiotics covering 
the most common pathogens (E. coli, S. aureus, S. pneumoniae). Aminoglycosides should 
be used with care in myeloma patients due to renal impairment.130 In patients treated 
with high-dose steroids or bortezomib, the risk of viral infections such as HSV and 
VZV and of fungal infections should be taken into account. 
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1.6 Pneumococci and pneumococcal infections 
Streptococcus pneumoniae is a gram-positive coccoid bacterium of facultative anaerobic 
nature. The most significant character of almost all pneumococci is the polysaccharide 
capsule that surrounds the bacterial cell wall and provides protection against the host 
defense mechanisms of opsonization and phagocytosis. The pneumococci are divided 
into serogroups and serotypes based on the immunological profile of the capsule. 
Currently, 97 serotypes have been described.151 The distribution of pneumococcal 
serotypes displays natural fluctuations and geographical differences.152 
Different serotypes have different invasive potential. Serotypes associated with invasive 
disease are for example 1 and 7F, while serotypes such as 6B and 23F are commonly 
found in carriage.153 The rank order of serotype prevalence in invasive disease also varies 
with exposure and vaccination and forms the basis for selecting serotypes for inclusion 
in the pneumococcal vaccines. 
The polysaccharide capsule is the most important virulence factor of pneumococci. 
Besides inhibiting complement and immunoglobulin binding to the bacterium, it 
prevents mechanical clearance by mucus secretion, restricts autolysis, and reduces 
exposure to antibiotics.47 Other pneumococcal virulence factors include the 
pneumococcal surface proteins A and C (PspA, PspC), which act partly by reducing 
complement activation.154 LytA, autolysin, is involved in cell wall degradation during 
bacterial division and lysis, and releases cytotoxins from the cell cytoplasm. The most 
important cytotoxin, pneumolysin, is a pore-forming exotoxin expressed by most 
invasive pneumococcal strains and capable of lysing host cells. Pneumolysin has many 
other functions including induction of ciliostatis and activation of inflammation, which 
promote bacterial invasion of the host.47 In addition, pneumococci have a high potential 
of incorporating genetic material such as antibiotic resistance genes and genes coding 
for capsular polysaccharides from other pneumococcal strains and streptococcal species, 
which may help them escape attempts of treatment and prevention.154 
Pneumococci are the major cause of community-acquired pneumonia world-wide, and 
bacteremia is seen in up to 15% of adult cases.151, 155 Carriage rates in adults are around 
10%, in toddlers and children in daycare up to 60%.47 Pneumococcal disease causes 
close to 1 million deaths per year in children less than 5 years old globally, 155 and the 
case-fatality rate in invasive disease remains high, especially in the elderly population.156 
The age distribution of infection is characteristic with the highest incidences in infants 
and old adults. Other risk groups include patients with immune deficiencies, such as 
primary and secondary hypogammaglobulinemia, complement deficiency, HIV, and 
functional or acquired asplenia. The marginal zone of the spleen is the most important 
site for effective killing of pneumococci, and asplenic patients are at significant risk of 
fulminant invasive infection.70 
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Hematological malignancies typically associated with a high risk of pneumococcal 
infection are multiple myeloma, chronic lymphatic leukemia, and lymphoma. They 
encompass a wide spectrum of immune disturbances, but defective antibody production 
is considered the most important cause for susceptibility to pneumococcal infection. An 
incidence of invasive pneumococcal disease (IPD) in patients with hematological 
malignancies of 500-700 cases/100.000 per year has previously been described.45, 157 
However, a recent Swedish study showed an attack rate in multiple myeloma as high as 
2238 cases/100.000 per year, compared to 15 cases/100.000 per year in the general 
population and 45/100.000 in adults ≥ 65 years of age.156  
 
1.7 Pneumococcal vaccination 
1.7.1 Evaluation of vaccine responses 
The benefit of vaccination at the group level is preferably evaluated by clinical 
endpoints, i.e., reduced incidence of the infectious disease in question. However, such 
studies are difficult to perform not least in risk groups such as patients with specific 
immunodeficiencies since they require very large numbers of participants. Instead, for 
the assessment of pneumococcal vaccine responses, two conceptually different 
laboratory methods are being used. Quantitative antibody titers are measured by 
enzyme-linked immunosorbent assays (ELISA) while qualitative opsonophagocytosis 
assays (OPA) estimate the level of antibody-mediated killing of pneumococci.  
The serotype-specific pneumococcal ELISA has been widely used in vaccine studies due 
to its relative simplicity and cost-effectiveness. The first generation of this assay suffered 
from low specificity because it also measured antibodies directed against the 
pneumococcal cell wall polysaccharide (CPS) prevalent in all pneumococci. This was 
largely overcome by preadsorption of sera with purified CPS, and the specificity of the 
assay has been further enhanced by the addition of preadsorption of serotype 22F 
capsular polysaccharide.158 OPA methods can be of “killing type”, estimating the sum of 
opsonophagocytosis and bactericidal capacity, or flow cytometric, estimating only 
opsonophagocytic capacity; the killing type is preferred.159 These analyses are more 
complex and time-consuming than the ELISA, but represent an in vitro model of what 
are considered the principal host defense mechanisms against pneumococci. Multiplex 
OPA analyses have been developed and have largely replaced the ELISA in the licensing 
of new pneumococcal conjugate vaccines.  
A pneumococcal antibody concentration of ≥ 0.35 g/ml, aggregated across all 
serotypes included in PCV7 has been accepted as a correlate of protection against IPD 
in infants.160 This titer has been proposed to correspond to an OPA titer of 1:8 in young 
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children.159 Since there are differences between serotypes regarding the amount of 
antibody required for protection the aggregate correlates have recently been refined, and 
serotype-specific thresholds for both ELISA and OPA titers in infants have been 
proposed.161 Correlates of protection have not been defined for adult populations. Many 
older adults have high levels of naturally acquired pneumococcal antibodies, and it is 
anticipated that OPA provides a better correlate of protection than ELISA in this 
population.71 In general, it is likely that elderly individuals require higher antibody and 
OPA titers for protection than what is indicated by the infant thresholds. 
1.7.2 Pneumococcal polysaccharide vaccines 
Polysaccharide vaccines to pneumococci have been available since the 1970s. The 
current 23-valent vaccine (PPV) was licensed in 1983. It includes purified 
polysaccharides from 23 of the most prevalent serotypes in invasive pneumococcal 
disease (IPD) at the time of licensure. A serotype coverage of 85-95% in IPD has been 
described in different countries before the introduction of pneumococcal vaccination in 
childhood immunization programs.71, 162 The vaccine has been widely used in elderly and 
immunocompromised patients, and is recommended by the CDC and the WHO, as well 
as by Swedish authorities.163-165 The most recent Cochrane meta-analysis from 2013 
estimated that PPV has a protective efficacy of 74% against invasive pneumococcal 
disease in adults.84 However, the vaccine efficacy against pneumococcal and all-cause 
pneumonia and mortality in pneumococcal infections is uncertain, especially in elderly 
patients and adults with chronic diseases, i.e., the populations for whom vaccination is 
recommended.71, 84, 85  Due to its T cell-independent mode of action, PPV is poorly 
immunogenic in children < 2 years of age.  
The PPV does not induce an immunological memory; however, pneumococcal antibody 
titers have been shown to persist above vaccine-naïve levels for at least 5 years and 
against most serotypes in adults ≥ 65 years.166  
A subject of much debate in the use of PPV is the risk of hyporesponsiveness, referring 
to lower immune responses after repeat vaccine doses. This phenomenon was initially 
described for polysaccharide meningococcal vaccines, and the theory has been that the 
already existing pool of switched memory B cells is successively depleted after exposure 
to large amounts of polysaccharide antigen which drives the cells into terminal 
differentiation without being able to induce new memory cells. An immunologic 
explanation was launched by Clutterbuck et al., who found decreased levels of memory 
B cells and higher numbers of plasma cells after PPV vaccination compared to 
vaccination with a conjugate pneumococcal vaccine.68 However, primary vaccination 
with PPV as well as boosting with the same vaccine, has been shown to evoke 
significant titer increases,166 and with a longer interval between the doses (5-10 years) 
immune responsiveness is not depressed.167 Importantly, the clinical relevance of 
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hyporesponsiveness is not known. Nevertheless, since the same phenomenon has been 
demonstrated when PPV has been administered before a pneumococcal conjugate 
vaccine (PCV), it is recommended that when the vaccines are given in series the PCV 
should always precede the PPV.164  
1.7.3 Pneumococcal conjugate vaccines 
Pneumococcal conjugate vaccines were developed in order to protect small children 
against severe disease. The first, seven-valent conjugated vaccine (PCV7) included 
serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F individually conjugated to the diphtheria 
carrier protein CRM197. These serotypes caused 80-90% of IPD in children in the 
United States at the vaccine introduction.71 
The vaccine was included in the US childhood vaccination program in 2000 and resulted 
in a dramatic decline in infant IPD.168 Effects on pneumonia, otitis media and 
nasopharyngeal carriage in children were also shown.71 In addition, indirect herd 
immunity was seen in unvaccinated adults, with a marked decline of IPD in all age 
groups, not least among persons ≥ 65 years of age, in whom vaccine-serotype and all-
serotype IPD had decreased by 92% and 37%, respectively, nine years after vaccine 
introduction.169 These effects have continued after the introduction of an expanded 
conjugated vaccine (PCV13) including 6 additional serotypes (1, 3, 5, 6A, 7F, 19A), see 
Figure 8.170 
 
 
 
 
 
 
 
 
 Changes in the incidence of invasive pneumococcal disease among American adults ≥ 65 years of Figure 8.
age, 1998-2013. Blue bars = IPD caused by all serotypes; red bars = IPD caused by PCV13 serotypes. 
Reprinted with permission of Elsevier.170 
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PCV7 was incorporated in the Swedish childhood vaccination program between 2007 
and 2009 and has later been replaced by 10-valent PCV or PCV13. Due to a partly 
different serotype distribution, the PCV7 coverage in IPD was only about 50-60% in 
Swedish children before general childhood vaccination.162, 171 Despite this, effects similar 
to those seen in the US regarding infant and herd immunity have recently been 
described.151 However, this study could not document a reduction in the incidence of 
overall IPD in adults ≥ 65 years of age, which was due to a large increase in non-PCV13 
strains. This clearly illustrates the matter of serotype shift, which has been a major 
concern since the introduction of childhood PCV vaccination. Strains that increased 
after PCV7 introduction, typified by the penicillin non-susceptible 19A serotype, have 
again decreased after the introduction of PCVs of higher valencies.151, 170 The Swedish 
study by Galanis et al. describes increasing serotype diversity after PCV13 introduction 
with a high incidence of strains included only in PPV.151 
The immunologic advantages of PCVs including the capability of inducing immunologic 
memory have driven the question of PCV vaccination in adults and elderly. A large 
clinical trial (CAPiTA) evaluated the impact of PCV13 vaccination on pneumococcal 
disease in adults ≥ 65 years of age, and demonstrated a vaccine efficacy of 46% and 75% 
against vaccine-type pneumonia and IPD, respectively.86 Based on these results, the 
CDC recommendations on pneumococcal vaccination in elderly were revised, and now 
include one dose of PCV13 followed by one dose of PPV after 6-12 months.164 
However, it should be pointed out that the CAPiTA study did not include a PPV study 
arm but only compared PCV13 to placebo. Also, the herd effects of childhood PCV 
vaccination as well as the shift in serotype distribution, illustrated by the fact that only 
32% of IPD cases in an elderly Swedish population were caused by PCV13 strains 
already 5 years after PCV13 introduction,151 raise questions as to the future benefit of 
PCV13 vaccination in adults, and underline the importance of surveillance. 
The use of pneumococcal conjugated vaccines in immunocompromised patients is 
attractive, not least since PPV responses in these patients are often poor, and the 
conjugated vaccine type has been recommended by the CDC since 2012.137 However, 
the literature on PCV superiority to PPV is inconsistent.172 The CAPiTA study was not 
designed to show vaccine efficacy in immunocompromised hosts and the number of 
immunosuppressed patients was small. This aside, no effect on pneumococcal disease of 
a single dose of PCV13 was shown.86  
Regarding patients with hematological malignancies, studies of allogeneic stem cell 
transplanted patients using repeat doses of PCV7 have shown slightly better antibody 
responses than what has been described after PPV vaccination.173-176 However, 
comparisons are difficult since different vaccination regimes and definitions of response 
have been used. Also, lower serotype coverages of PCV13 and PPV have been described 
in hematological patients than in the general adult population,177 and the current 
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knowledge raises more questions than it gives answers as to how these patients are best 
protected against pneumococcal infection. The development of conjugated vaccines is 
technically difficult, and also with a serotype expansion the issue of serotype shift will 
persist. New vaccine candidates including protein-based antigens and whole-cell 
vaccines are currently being investigated.178 However, at present, combination strategies 
of PCVs and PPV should be the preferred alternative in B cell malignancies and other 
immunosuppressive disorders in order to obtain the immunologic advantages of PCVs 
and the broad serotype coverage induced by PPV. 
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2 Hypotheses and aims 
The main purposes of this thesis were to identify risk pathogens in patients with B cell 
malignancies and disorders, and to investigate their responsiveness to pneumococcal 
vaccination. An increased knowledge in this field could help in preventing and treating 
infectious complications, and hopefully contribute to a reduced morbidity and mortality 
among these immunocompromised patients. 
The thesis is based on the following hypotheses:  
 Antimicrobial humoral immunity is depressed in elderly patients with 
multiple myeloma but also in patients with Waldenstrom’s 
macroglobulinemia and MGUS 
 Levels of antibodies towards encapsulated bacteria, such as pneumococci 
are particularly low among these patients 
 Pneumococcal vaccine responses are reduced in elderly patients with B 
cell malignancies and disorders compared to healthy age-matched 
controls 
 A conjugated pneumococcal vaccine evokes higher post-vaccination 
antibody titers in these patients compared to a polysaccharide 
pneumococcal vaccine 
 ELISA measurements may overestimate post-vaccination anti-
pneumococcal immunity in patients with B cell malignancies  
 Anti-pneumococcal IgM antibodies may show a better correlation with 
opsonophagocytic killing activity than IgG antibodies do in patients with 
B cell malignancies 
 Multiple myeloma patients with high disease activity are more susceptible 
to respiratory viral infections and secondary bacterial complications than 
patients with low disease activity 
 Multiple myeloma patients with positive respiratory virus tests have 
higher rates of hospitalization and mortality than patients with negative 
respiratory virus tests  
To test these hypotheses, the thesis had the following specific aims: 
 Investigation of the serologic immune status to a wide range of bacteria, 
viruses, and fungi in patients ≥ 60 years of age with multiple myeloma, 
Waldenstrom’s macroglobulinemia, and MGUS in comparison to an age-
matched control group 
 Vaccination of these patients and age-matched controls with one dose of 
either conjugated or polysaccharide pneumococcal vaccine 
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 Evaluation of pneumococcal vaccine responses by measurement of 
serotype-specific IgG and IgM antibodies and of functional antibody 
activity by opsonophagocytosis (OPA) 
 Correlation of anti-pneumococcal IgG and IgM concentrations measured 
by ELISA, and OPA titers for different pneumococcal serotypes in 
patients and controls 
 Retrospective assessment of the prevalence of respiratory viruses in 
multiple myeloma patients, and 
 Identification of a possible association between positive respiratory virus 
tests and disease activity, hospitalization, mortality, and other parameters 
such as age and subsequent bacteremia  in these patients 
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3 Patients and methods 
3.1 Patient populations 
All study persons in papers I-III were recruited from the Department of Hematology, 
Uddevalla hospital, Uddevalla, Sweden between May 2008 and March 2009. WHO 
criteria were used to establish the hematologic diagnoses (multiple myeloma, 
Waldenstrom’s macroglobulinemia, MGUS).179 In total, 81 persons aged ≥ 60 years 
were primarily included, 25 with a diagnosis of multiple myeloma (MM), 16 WM, 18 
MGUS, and 22 age-matched controls without hematological disorders and from the 
same geographic area, most commonly the spouse of the patient. Since the focus of 
these studies was elderly patients with as little immunosuppression as possible, patients 
< 60 years of age and patients who had undergone high-dose chemotherapy followed by 
ASCT were excluded. Further exclusion criteria were pneumococcal vaccination or 
infection (pneumonia, septicemia, meningitis) within a year prior to the study, and 
previous severe adverse reactions to any kind of vaccination. All participants gave 
written informed consent. 
Two control persons were excluded from the study, one who withdrew, one who had 
not turned 60 on the day of inclusion. For paper II, three more participants were 
excluded; one WM patient who dropped out before the second study visit, one MM and 
one MGUS patient each who turned out to have had pneumonia within a year before 
inclusion. For paper III, 15 patients from each study group were randomly selected for 
re-analysis of their post-vaccination serum samples. 
 
 
 
 
 
 
 
 Patient populations paper I-III. Figure 9.
 
Paper I 
Paper II 
Paper III 
N = 79 
25 MM 
24 MM 
15 MM 
16 WM 
15 WM 
15 WM 
18 MGUS 
17 MGUS 
15 MGUS 
20 Controls 
20 Controls 
15 Controls 
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In paper IV, all patients with a diagnosis of multiple myeloma who had been sampled 
for any analysis of respiratory viruses at the Sahlgrenska University Hospital, Göteborg, 
Sweden between January 2005 and December 2012 were included in retrospect. The 
cohort comprised 55 patients. Informed consent was waived since we had no contact 
with the study persons. 
3.2 Sampling and vaccination (paper I-III) 
The study persons were sampled pre-vaccination and randomized to receive a single 
dose of either the conjugated pneumococcal vaccine (Prevenar; Pfizer) or the poly-
saccharide pneumococcal vaccine (Pneumo23; Sanofi Pasteur) given intramuscularly. At 
the follow-up visit 4-8 weeks later, a post-vaccination serum sample for pneumococcal 
serology was taken. 
Pre-vaccination blood samples were directly analyzed for routine hematological 
parameters (blood hemoglobin concentration, white blood cell counts, platelet counts, 
blood differential counts) and serum concentrations of immunoglobulins and M-protein 
at the local hospital laboratory. Serum was separated and stored at -200 C until further 
analyses. 
For paper I, serum was analyzed for antibodies towards 24 different pathogens (bacteria, 
viruses, fungi, and Toxoplasma gondii) by validated methods at the Departments of 
Clinical Bacteriology and Virology, Sahlgrenska University Hospital. For paper II, pre-
and post-vaccination serum samples were transported frozen to Statens Serum Institute, 
Copenhagen, Denmark and analyzed with serotype-specific pneumococcal ELISA. The 
opsonophagocytosis assay was performed in part at the National Institute for Health 
and Welfare, Helsinki, Finland and in part by our research group at the Department of 
Clinical Bacteriology, Sahlgrenska University Hospital. For paper III, post-vaccination 
sera were shipped frozen to the Institute of Child Health, University College London, 
UK for re-analysis by multiplex OPA. Since the antibodies that mediate 
opsonophagocytosis might be of any isotype, the analysis of serotype-specific IgM by 
ELISA was additionally performed at the Institute of Child Health in London and added 
to the previous IgG data. 
3.3 Clinical data 
For paper I-III, some clinical data were obtained via a patient questionnaire, e.g., 
previous immunizations, ongoing medication, and smoking habits. At the follow-up visit 
the patients were asked about adverse events after the vaccination. Further information 
regarding serious adverse events up to three months after the study termination, as well 
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as information about disease type and previous and ongoing chemotherapy or 
immunomodulatory therapy was retrieved from the patients’ records. 
For paper IV all analyses of respiratory viruses were extracted from a larger database 
containing all clinical virological assay results (n = 9885) registered for patients with a 
confirmed diagnosis of multiple myeloma between 1990 and January 2013 at the 
Sahlgrenska University Hospital. A multiplex PCR method for analysis of respiratory 
viruses was introduced in 2005 at the Department of Clinical Virology. Because of this, 
we chose to investigate the database for respiratory virus analyses from January 2005 
until the last registered sample in September 2012. The study stop date was set three 
months later. 
Patient data regarding age, sex, serum (S)-IgG and M-protein concentration, white blood 
cell counts (WBC), blood cultures, autologous stem cell transplantation, hospitalization, 
and death were retrieved from medical records. The recorded blood tests were selected 
as close to but not more than four weeks from when the respiratory virus sample was 
collected. Blood cultures taken within a week from the respiratory virus test were 
registered. 
3.4 Laboratory methods 
3.4.1 Serotype-specific ELISA (IgG, IgM) 
In paper II, serotype-specific antibodies towards the seven pneumococcal serotypes 
present in the two study vaccines (4, 6B, 9V, 14, 18C, 19F, and 23F) were measured by 
an in-house ELISA at Statens Serum Institut, Copenhagen.180 ELISA microplates were 
coated with 100 l pneumococcal polysaccharide in phosphate buffered saline (PBS) 
overnight at 4-60C and then washed with a washing buffer containing PBS and 0.1% 
Tween 20. Sera were blocked for the pneumococcal-specific C-polysaccharide (CPS), 
which occurs naturally in human serum and may interfere with the detection of capsular 
polysaccharides, by adding 50 l of a 0.2% CPS solution to 1 ml serum. Serum was 
tested in two-fold dilutions starting at 1:100.  
100l serum was added to each microplate well followed by 1.5 h incubation at room 
temperature. The plates were washed before addition of 100 l conjugate (horseradish 
peroxidase-conjugated rabbit anti-human IgG, swine anti-rabbit IgG), again incubated 
and washed, and finally 100 l of substrate (o-phenylenediamine) was added. After 30 
min of incubation on a shaker, the enzyme reaction was stopped by adding H2SO4. 
Optical densities (ODs) were measured at 490 nm. A local reference serum calibrated to 
the US standard reference serum 89-SF was used for creating a standard curve. 
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In paper III, sixty post-vaccination sera were assayed at the Institute of Child Health, 
University College London, for serotype-specific IgM antibodies to serotypes 4, 6B, 14 
and 23F using an in-house ELISA, adapted from the WHO reference IgG ELISA.181 
IgM plates were incubated with alkaline phosphatase-conjugated goat anti-human IgM 
antibody (SIGMA, Saint Louis, MO, USA) at 1:3000 in antibody buffer for 2 hours at 
room temperature. Antibodies were detected following incubation with substrate 
solution and ODs were read at 405 nm.  
3.4.2 Opsonophagocytosis 
In paper II functional antibody activity was investigated by a modified multiplexed 
opsonophagocytosis assay (OPA) as previously described.182, 183 The first 16 sera were 
analyzed for four pneumococcal serotypes (4, 6B, 14, 23F), the remaining samples with 
the same method but only for serotypes 4 and 14. Pneumococcal strains of serotypes 4, 
6B, 14, and 23F made resistant to one of four antibiotics (optochin, spectinomycin, 
streptomycin, trimethoprim) were obtained from BEI Resources (Manassas, VA, USA), 
promyelocytic HL-60 cells used as phagocytes were obtained from ATCC (Manassas, 
VA, USA), and baby rabbit complement from Invitrogen (Lidingö, Sweden). The HL-60 
cells were cultivated for about 8 weeks and investigated for viability and by flow 
cytometry for surface receptors CD11b, CD35, and CD71 weekly to decide when they 
fulfilled the acceptance criteria for differentiation.  
For the OPA, heat-inactivated serum samples (20 l) were tested in eight 3-fold 
dilutions in 96-well plates. A 10 l-suspension of target pneumococci was added to each 
well after centrifugation and washing twice with opsonobuffer (Hanks’ balanced salt 
solution (HBSS), sterile water, and fetal bovine serum), and dilution to the proper 
bacterial density (2 x 105 CFU/ml). Meanwhile, HL-60 cells were washed with HBSS 
twice. After incubation of the serum samples with bacteria for 30 min at room 
temperature, 10 l of complement and 40 l of HL-60 cells (8 x 105 cells) were added to 
each well followed by incubation at 370 C in 5% CO2 with shaking 220 rpm for 45 min. 
The microtiter plates were then placed on ice and 10 l of the final mixture from eight 
wells was plated on four different antibiotic-containing agar plates (Todd-Hewitt broth-
yeast extract, THYE). The plates were incubated overnight at 370 C in 5% CO2, 
photographed, and the number of bacterial colonies counted manually. Opsonization 
titers were defined as the inverse of the serum dilution that killed 50% of the bacteria. 
The lowest OPA titer that could be determined was 4. 
Each plate contained four complement controls without serum and two bacterial 
controls without serum and complement. Six patients were treated with antibiotics 
during the study. To exclude the possibility that residual concentrations of antibiotics 
had interfered with the OPA the bactericidal effect of these sera was tested alone (test 
wells containing serum, bacteria, and buffer) and compared to the complement controls 
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of the standard assay (test wells containing bacteria, HL-60 cells, complement, and 
buffer). Since no significant OPA titer differences were found, these samples were not 
excluded from the study.  
The OPA performed in London for paper III used the same multiplexed killing-type 
method with slight modifications.184  
 
 
 
 
 
 THYE plate with eight 3-fold dilutions of serum from left to right. Figure 10.
3.4.3 Multiplex PCR 
The multiplex real-time PCR for respiratory viruses used in paper IV is an in-house 
method developed at the Department of Clinical Virology, Sahlgrenska University 
Hospital.185, 186 It was introduced in 2005 and initially analyzed influenza A and B 
viruses, parainfluenza virus 1-3, metapneumovirus, and respiratory syncytial virus, but 
has gradually expanded to include rhinovirus, enterovirus, adenovirus, coronavirus 
(CoV)-229E, CoV-OC43, CoV-NL63, CoV-HKU1, bocavirus, and also Mycoplasma 
pneumoniae, Chlamydia pneumoniae, and Bordetella pertussis. Primers and probes were 
obtained from the literature or developed in the local laboratory.  
In the most updated version of the method,186 nucleic acid was extracted from 200 l of 
specimen by a Magnapure robot (Roche Diagnostics, Mannheim, Germany) using the 
Total Nucleic Acid isolation kit and eluted in a 100 l volume. A volume of 5 l was 
used for the PCR, which was performed in a 7900 real-time (RT) PCR system (Applied 
Biosystems, Foster City, USA) in 8 parallel reactions of final volumes of 20 l 
containing primers and RT-PCR master mix (Applied Biosystems) besides the nucleic 
acid. Reverse transcription was performed at 460C for 30 min. After 10 min of 
denaturation at 950C, the PCR was performed in two steps (15 s 950C, 60 s 580C) and 
for 45 cycles. As multiplexing tends to decrease the amplification, the reagents were 
evaluated in comparison to separate reactions by the use of pUC57 plasmids with inserts 
of the targeted viral sequences (GenScriptCorp, Piscataway, NJ, USA). The 
combinations were accepted if the cycle threshold (Ct) value was not more than two 
cycles higher than in a singleplex reaction. 
3-fold dilutions 
1:4 
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3.5 Statistical methods 
3.5.1 Univariate analyses 
Median antibody titers were calculated in paper I, geometric means with 95% 
confidence intervals for pneumococcal ELISA and OPA titers in papers II and III. 
Antibody and OPA titers below the detection limit were set to 0.5 times this limit; 
antibody titers above the detection limit were assigned the titer of this limit for statistical 
calculations. In papers I-III, the Mann-Whitney U test was used to compare means 
between groups. Paper IV only included patients with the same diagnosis (multiple 
myeloma). We assumed a normally distributed cohort and in this case used the Student’s 
t test for comparisons of means. The Wilcoxon signed rank test was used for 
comparisons of paired data, Fisher’s exact test for comparisons of categorical variables, 
and the Spearman rank correlation test for determination of correlations between 
datasets. All analyses were performed using Graph Pad Prism software (GraphPad, San 
Diego, CA, USA). A P value of < 0.05 was considered to be statistically significant 
except in paper I, where a significance level of P < 0.01 was chosen to compensate for 
multiple analyses. 
3.5.2 Multivariate analysis 
In paper II a multivariate projection analysis, Orthogonal Partial Least Squares (O-PLS) 
to latent structures, was used (SIMCA P, Umetrics, Umeå, Sweden). This is a method of 
visualizing patterns in complex datasets and gives a picture of how the data covariates 
rather than calculating exact P values. O-PLS is a regression and prediction variant of 
principal component analysis that relates X data to Y variables and separates the data 
into predictive and uncorrelated information.187 We used the vaccine response as 
measured by OPA titers to pneumococcal serotype 14 as Y variable and all remaining 
patient data as X variables. X variables that were positively or negatively associated with 
Y in the multivariate model were further analyzed by univariate methods. 
3.5.3 Survival analysis 
In paper IV overall survival was calculated using the Kaplan-Meier log rank method for 
comparison of curves in patients with ≥ 1 positive RV test vs. patients with no positive 
RV test (Sigma Plot 12.5, Systat Software Inc, San José, CA, USA). Overall survival was 
calculated from the first and from the last respiratory virus test, respectively. Follow-up 
time was defined as the date of these tests to the study stop date or to date of death if 
earlier. 
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4 Results and discussion 
4.1 Humoral immunity to infectious agents in B cell 
disorders (paper I) 
In paper I we investigated the prevalence and levels of serum IgG antibodies towards 24 
different pathogens in 79 study persons; 25 with a diagnosis of MM, 16 with WM, 18 
with MGUS, and 20 control persons.  
The study groups were comparable regarding sex and there were no significant age 
differences between the groups. However, the median age was somewhat higher in MM 
and WM patients (77 years) than in MGUS patients (71 years) and control persons (69 
years). Since the spectrum of infections among elderly overlap with that of patients with 
B cell malignancies,4, 72 and a decline in specific antibody titers with increasing age has 
been shown,72 it is possible that these differences affected our results. A large number of 
the patients had hypogammaglobulinemia, which was expected in the MM (92%) and 
WM patients (44%), but higher in the MGUS patients (56%) than what is commonly 
described (25-30%).95 Sixteen MM patients (64%) and one WM patient had ongoing 
chemotherapy or immunomodulatory therapy, while three MM patients (12%) and eight 
WM patients (50%) were treatment-naïve.  
In general, the MM patients showed the most depressed pathogen-specific antibody 
titers, which was expected and in accordance with previous findings of infectious 
susceptibility in B cell disorders.107, 108 Treatment-induced immunosuppression clearly 
contributed, since almost two thirds of the MM patients had ongoing therapy. 
Moreover, there was a tendency towards higher antibody titers among the treatment-
naïve MM and WM patients. On the other hand, MM patients are known to have a 
continuously increased risk of infection including during the plateau phases of the 
disease.19 WM and MGUS patients also had significantly suppressed humoral immunity 
to a number of pathogens when compared to the control subjects, with surprisingly low 
antibody levels in especially the MGUS group. This certainly mirrors the high degree of 
hypogammaglobulinemia among our MGUS patients but also supports the notion that 
these patients, despite a non-malignant underlying B cell condition, are at increased risk 
of contracting and succumbing to infectious diseases.39, 116 Co-morbidities such as 
autoimmune diseases and other types of malignancies, which are seen in increased 
numbers in MGUS patients, might contribute to the infectious susceptibility.36 
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Four antibody patterns could be discerned from our serological analyses. The first 
pattern, a stepwise antibody titer increase from MM patients to control subjects, was 
seen for pneumococci, S. aureus alpha-toxin, tetanus toxoid, diphtheria toxoid, VZV, and 
mumps and rubella viruses.  
 
 
 
 
 
 
 Antibody titers to pneumococci and VZV. Each triangle represents one individual. Open Figure 11.
triangles represent treatment-naïve MM and WM patients. Horizontal bars denote study group medians.  
(A) Anti-pneumococcal IgG to pneumococcal polysaccharide (PPS). (B) Anti-VZV IgG. The dotted line 
indicates the cut-off level for protective immunity (400).  **, P < 0.01; ***, P < 0.001. 
Regarding pneumococci, serum antibody titers were 15-fold lower among MM patients 
and 5-fold lower among WM patients compared to the control group (P < 0.0001,        
P = 0.002, respectively). Low levels of baseline anti-pneumococcal antibodies have 
previously been described in MM patients and have been associated with severe 
pneumococcal disease.19, 131 WM and MGUS patients have an increased incidence of 
pneumonia, presumably caused by pneumococci.5, 6 This fits with our findings of 
depressed antibody titers in all disease groups and raises the question of pneumococcal 
vaccination in elderly patients with B cell disorders. Staphylococcal alpha-toxin antibody 
levels were lower than an age-stratified median in all three patient groups, which might 
have a clinical implication, since low initial antibody titers have been shown to correlate 
with complicated bacteremia and high mortality.188 Protective antibody titers to tetanus 
and diphtheria were surprisingly low in all study groups highlighting the need for 
(re)vaccination in this age group at possible exposure to the pathogens. Immunity to 
tetanus ranged from 8% in MM patients to 65% in control subjects, immunity to 
diphtheria from 4% in MM patients to 35% among the controls.  
VZV antibody titers were 8-fold higher in control subjects than in MM patients            
(P = 0.006). In contrast to the other investigated viruses, there was a loss of humoral 
immunity in MM as well as in WM patients with a seropositivity of 68% in MM and 
75% in WM patients, while MGUS patients and controls reached normal adult levels 
(94% and 100%, respectively). VZV antibodies have been shown to neutralize the virus 
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at inoculation sites upon re-exposure.189 VZV reactivation in the form of shingles is 
common in the elderly and of increasing incidence in MM and WM patients with the use 
of bortezomib,72, 106 but has been attributed to diminished cell-mediated immunity rather 
than loss of antibodies.189 However, it is plausible that the patients with the most 
depressed humoral immunity also had impaired T cell functions, and our results support 
the use of prophylactic aciclovir in these patients.  
The second antibody pattern displayed more depressed titers in MM and MGUS 
patients than in the WM and control groups, and included S. aureus teichoic acid, 
Moraxella catarrhalis, Candida, Aspergillus, and measles virus. Again, the MM group had 
the most suppressed antibody levels to all antigens.  
 
 
 
 
 
 
 Antibody titers to Candida and Aspergillus. Each triangle represents one individual. Open Figure 12.
triangles represent treatment-naïve MM and WM patients. Horizontal bars denote study group medians.  
(A) Anti-Candida IgG. (B) Anti-Aspergillus IgG.  Titers between the dotted lines are considered borderline, 
titers below the lower line negative, titers above the higher line positive, in the case of Candida with respect to 
ongoing infection. **, P < 0.01; ***, P < 0.001. 
Regarding staphylococcal teichoic acid, a 4-fold higher antibody level was seen in the 
control group compared to the MM group (P < 0.0001), and only two MM patients 
reached the age-stratified population median. The background antibody titers to fungal 
antigens were very low especially in MM but also in MGUS patients, as shown in Figure 
12. Fungal infections typically affect patients with B cell malignancies following 
prolonged chemotherapy-induced neutropenia, high-dose corticosteroid treatment, and 
stem cell transplantation.106 Anti-Candida antibodies have a protective potential 
regarding disseminated disease,190 and our results suggest an increased susceptibility 
among all patient groups. 
The third antibody pattern showed measurable and comparable antibody levels among 
all study groups, and included H. influenzae type b (Hib), Borrelia, CMV, Epstein Barr 
virus (EBV), HSV1, human herpesvirus type 6 (HHV6), and Toxoplasma. In contrast to 
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pneumococci and staphylococci, Hib antibody concentrations did not differ significantly 
between the study groups (Figure 13A). Although no participant reported previous 
vaccination, 80% of MM patients, 88% of WM patients, and 100% of MGUS patients 
and controls had antibody titers above the generally accepted minimum level for 
protection against invasive Hib infection (> 0.15 mg/L). This is comparable to a healthy 
adult population.191 Hib infections have been frequently reported in older studies of 
MM patients,18, 111 which could still motivate vaccination. However, after the 
introduction of Hib vaccine in childhood immunization programs, Hib has been largely 
replaced by other, non-capsulated H. influenzae strains also in adults.138  
 
 
 
 
 
 
 Antibody titers to H influenzae type b (Hib) and Borrelia. Each triangle represents one Figure 13.
individual. Open triangles represent treatment-naïve MM and WM patients. Horizontal bars denote study 
group medians.(A) Anti-Hib IgG. The dotted line indicates a minimum protective antibody level (0.15).   
(B) Anti-Borrelia IgG. The dotted line indicates the seropositivity level (15 AU/ml). 
Many of our study persons live in rural areas on the Western coast of Sweden, where 
Borrelia is endemic and the cause of both clinical and subclinical infections. We found 
an overall seropositivity rate of 27% with cases in all study groups and unexpectedly 
high antibody titers (Figure 13B). No patient reported previous invasive borreliosis or 
ongoing symptoms; a few had been treated previously for erythema migrans. Borrelia 
antibody titers are known to persist over many years,192 and our findings illustrate the 
difficulties of using serological analyses to diagnose current Borrelia infection. 
Antibody titers to HSV1, CMV, and EBV were high in all study groups with an overall 
seroprevalence of 86%, 75%, and 84%, respectively. Viral antibody levels are known to 
be stable over time,193 which was confirmed in our study and did not seem to be 
drastically affected by the immunosuppressed state of the patients. With the exception 
of VZV, we found high and virtually comparable seroprevalence rates among the study 
groups also for the other investigated viruses (measles, mumps, rubella, HHV6), 
although there were group differences regarding the absolute antibody titers. Actually, 
antibody titers to CMV and HSV1 tended to be higher in the patient groups than among 
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the controls, which might reflect a higher number of viral reactivations in the 
immunocompromised hosts resulting in antibody boosting. 
The last antibody pattern that was discerned from our data was characterized by an 
absence of antibodies in all study groups and rather reflected lack of exposure to the 
pathogens (i.e., HSV2 and various gut pathogens) than waning antibody titers. 
Antibodies towards the streptococcal antigens streptolysin O and DNase B were seen in 
a few individuals and of low levels, which is consistent with previous findings in adult 
populations of developed countries.194 
In summary, we found suppressed humoral immunity among our disease groups to 
many of the investigated pathogens, in particular to S. aureus, pneumococci, and VZV. 
Not only MM but also WM and MGUS patients showed clearly depressed specific 
antibody titers, which underlines an increased susceptibility to infections in these various 
B cell disorders. 
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4.2 Pneumococcal vaccination in B cell disorders      
(paper II) 
In paper II we investigated pneumococcal vaccine responses to a single dose of either 
the 7-valent conjugated vaccine (Prevenar; PCV7) or the 23-valent polysaccharide 
vaccine (Pneumo23; PPV) as measured by serotype-specific ELISA and opsono-
phagocytosis (OPA) in elderly patients with MM, WM, and MGUS compared to age-
matched controls.  
The study participants were the same as in paper I except for one drop-out and two who 
fulfilled the exclusion criteria, see Patients and methods. Clinical data are shown in 
Table 1. Almost two thirds of the MM patients (63%), but only one WM patient had 
ongoing chemotherapy or immuno-modulatory treatment at the time of vaccination. 
Hypogammaglobulinemia was seen in 92% of MM patients, 40% of WM patients, and 
53% of MGUS patients.  
Table 1. Study group characteristics. 
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As expected, with respect to their profound immune suppression, pneumococcal IgG 
concentrations before as well as after vaccination were the lowest among the MM 
patients. The same stepwise antibody pattern as was shown by using a multiplex 
serotype pneumococcal ELISA in paper I was evident at the serotype level, with the 
lowest antibody titers in MM patients followed by WM, MGUS, and controls. Data for 
responses to pneumococcal serotype 14 are shown in Figures 14 A and B.  
 
 Anti-pneumococcal IgG and OPA titers to serotype 14 before and after vaccination. MM, Figure 14.
multiple myeloma; WM, Waldenstrom’s macroglobulinemia; MGUS, monoclonal gammopathy of 
undetermined significance. (A) and (B), ELISA IgG; (C) and (D), OPA.(A) and (C), PCV7 vaccinees; 
(B) and (D), PPV vaccinees. Pre- and postvaccination titers for each individual are shown.   *, P < 0.05; 
**, P < 0.01.  
After vaccination, geometric mean IgG concentrations increased modestly in all study 
groups and irrespective of vaccine type given, with a maximum 4-fold titer increase. MM 
patients responded with a significant IgG increase to one serotype (18C), WM patients 
to three serotypes (9V, 18C, 19F), and MGUS patients and control subjects to all four 
serotypes (9V, 14, 18C, 19F). The poor vaccine responses in MM are consistent with 
findings in previous studies of the same patient category.19, 131  
A recurring problem when evaluating pneumococcal vaccine responses by using 
surrogate markers such as antibody and OPA titers instead of incidence of 
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pneumococcal infections is the lack of knowledge regarding cut-off levels for immune 
protection in adults. An IgG threshold of 0.35 g/ml has been correlated with 
protection against invasive pneumococcal disease in infants.160 Adults generally have 
higher background antibody levels against pneumococci than infants;195 however,  
vaccine studies of adults have used IgG cut-offs between 0.15 and 1.0 g/ml.88, 173 We 
chose two levels, 0.5 and 1.0 g/ml, which are in accordance with previous publications 
on adult immunocompromised patients.173, 174, 196 In total, 63% of our MM patients, 73% 
of the WM patients, 88% of the MGUS patients, and 100% of the control subjects 
responded with antibody levels ≥ 0.5 g/ml, and 38% (MM), 60% (WM), 65% 
(MGUS), and 80% (controls) ≥ 1.0 g/ml to all seven serotypes after vaccination. 
When comparing the vaccine subgroups (PCV7 vs. PPV recipients), baseline as well as 
post-vaccination antibody titers did not differ significantly for any of the study groups 
or pneumococcal serotypes, neither did the proportions of subjects with IgG antibody 
levels ≥ 0.5 g/ml and ≥ 1.0 g/ml. Antibody fold titer increases calculated for all 
seven serotypes combined were low in all study groups (geometric mean fold increases 
≤ 2) but there was a significant advantage of PCV7 in the WM group (1.62 vs. 1.32,      
P = 0.01) and of PPV in the MGUS group (1.30 vs. 1.83, P = 0.03) while the responses 
to the two vaccine types were equal in the control group. Regarding the MM group, two 
patients had very high IgG titers to all serotypes, one before and one after vaccination. 
These titers could not be confirmed by the functional antibody assay (OPA) and both 
patients had immunosuppressive treatment as well as hypogammaglobulinemia. The 
ELISA results were therefore suspected to be falsely high, and when these subjects were 
excluded, antibody fold increases were significantly higher among the PCV7 recipients 
also in the MM group (1.79 vs. 1.60, P = 0.04).  
Opsonophagocytosis assays have been shown to be the best functional correlate of 
protection against pneumococcal infection.159 When evaluating an elderly population, 
the use of an OPA is preferable since the functionality of IgG antibodies has been 
shown to wane with high age,197, 198 which also correlates with a higher incidence of 
pneumococcal disease.199 We chose to investigate a poorly immunogenic serotype (4), 
and a highly immunogenic one (14), which were both common in invasive 
pneumococcal disease in an elderly Swedish population at the time of the study.162 Our 
OPA results largely confirmed the results of the ELISA with lower OPA titers in all 
disease groups compared to the control group before as well as after vaccination, and 
generally the poorest titers were found among the MM patients, see Figures 14 C and D 
and Table 2. Significant OPA titer increases after vaccination were seen in MM and 
MGUS patients for serotype 14, and in control subjects for both serotypes. 
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Table 2. OPA titers before and after pneumococcal vaccination with either PCV7 or PPV. 
 
 
 
 
 
An OPA titer of 8 was chosen as cut-off in accordance with previous studies and as a 
possible equivalent of an IgG level of 0.35 g/ml. 159, 166, 200 In total, only 8% of the MM 
patients, 27% of the WM patients, 29% of the MGUS patients, and 55% of the controls 
reached this level for both investigated serotypes after vaccination. Regarding the 
vaccine subgroups, there was no trend favoring either of the two vaccines in any study 
group. The increases in absolute OPA titers were mainly achieved by the PCV7 vaccine 
in the MM patients, the PPV vaccine in the MGUS patients, and both vaccines in the 
control group. There were no significant differences in post-vaccination OPA titers, 
OPA fold titer increases, or proportion of patients with an OPA titer ≥ 8 between the 
vaccine subgroups. 
Since MM, WM, and MGUS are disorders of the B cell line we had anticipated that a 
conjugated pneumococcal vaccine, which elicits a T cell-dependent response, would be 
more immunogenic in the investigated patient groups than the polysaccharide vaccine. 
However, although there was possibly a slight trend towards better responses to PCV7 
in the more diseased study groups (MM, WM), our hypothesis could not be confirmed 
by the study data. The small series of patients in each vaccine subgroup might have 
contributed to this. Kumar et al. reported low but slightly better immune responses in 
allogeneic stem cell transplanted patients who had received one dose of PCV7 
compared to those who had been given PPV.176 However, the stem cell donor had 
received one dose of the same vaccine as the recipient before transplantation, which 
might have enhanced the PCV7 response. The use of a booster dose of either PCV7 or 
PPV after the first dose of conjugated vaccine would probably have increased the 
immune responses of our patients as has previously been shown for ASCT recipients 
and HIV patients.136, 196 Nevertheless, at the time of this study non-transplanted MM 
patients and WM patients in our region of Sweden were routinely vaccinated with one 
dose of PPV, and we wished to evaluate if a single dose of PCV7 was clearly superior to 
the prevailing vaccination regime, which our results did not support.  
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The multivariate O-PLS analysis of all data showed an association between good vaccine 
responses as measured by OPA and high levels of total serum-IgG and WBC, and no 
previous immunosuppressive treatment. Conversely, hypogammaglobulinemia, high 
levels of M-protein, and ongoing treatment, in particular with cyclophosphamide and 
dexamethasone, were negatively associated with vaccine responses. The same tendencies 
were seen in group-specific univariate correlation analyses and were expected. 
Hypogammaglobulinemia has previously been related to poor pneumococcal vaccine 
responses in patients with hematological malignancies.19, 173 Since 53% of our MGUS 
patients had hypogammaglobulinemia and the median level of M-protein was high      
(11 g/L), this is likely to have contributed to the lower vaccine responses in this patient 
group compared to the control group. Two thirds of the MM patients were on 
treatment at the time of vaccination, 40% of these with cyclophoshamide and 
dexamethasone, which partly explains the poor vaccine responses in this study group. In 
contrast to other studies,88, 173 we did not find a relation between age or sex and vaccine 
response. 
The vaccines were generally well tolerated among our study participants. In total five 
unforeseen hospitalizations were recorded during the three month follow-up period 
after vaccination, none of which was deemed as caused by the vaccine. One MM patient 
was diagnosed with pneumococcal sepsis two weeks after PCV7 vaccination. The 
patient lacked a measurable vaccine response, and since the pneumococcal strain was 
not serotyped it is not known whether it was included in the given vaccine.  
The main finding of this study was the suboptimal pneumococcal vaccine responses not 
only among MM patients but also in WM and in MGUS patients, who have to our 
knowledge not previously been studied in this respect. We could not demonstrate a 
superiority of either of the pneumococcal vaccine types given in single dosage. The 
incongruence between ELISA and OPA results in certain MM patients led us further to 
the investigations described in paper III.  
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4.3 Correlation between pneumococcal ELISA and 
opsonophagocytosis in B cell disorders (paper III) 
Paper III describes the correlation between the pneumococcal serotype-specific ELISA 
and a multiplexed opsonophagocytosis assay in vaccinated elderly patients with MM, 
WM, and MGUS, and age-matched controls.  
Fifteen patients from each disease group and 15 control subjects were randomly selected 
from the study population in paper II for re-analysis of their post-vaccination sera and 
correlation statistics. The gender distribution was largely equal between the study 
groups; 55% of all participants were females. Median age was higher in the MM and 
WM groups (80 and 75 years, respectively) than in the MGUS and control groups (71 
and 68 years; P < 0.05), which might have affected our results. Previous studies of 
pneumococcal vaccination in adults have shown poorer OPA responses in elderly 
compared to younger adults.71, 197, 201  
Our OPA analyses confirmed the pattern seen in paper II with lower functional 
antibody titers among all disease groups than in the control subjects. This was 
significant for all investigated serotypes (4, 6B, 14, 23F) in WM patients, for three 
serotypes among the MM patients, and for two serotypes among the MGUS patients. 
ELISA IgM antibodies were seen at very low levels in the MM patients (P < 0.05 for 
serotype 23F, P < 0.001 for the remaining three serotypes vs. control subjects), while 
the WM, MGUS, and controls had comparable IgM titers. This contrasted to the 
stepwise pattern again seen for the anti-pneumococcal IgG, with the lowest titers among 
MM (P < 0.05 for all serotypes vs. controls) followed by WM, MGUS, and control 
subjects. 
The given pneumococcal vaccines (PCV7, PPV) were evenly distributed in the study 
groups. Since no differences in either OPA or ELISA antibody titers were observed 
between the vaccine subgroups in any of the study groups these data were pooled for 
the correlation analyses. We found significant correlations between anti-pneumococcal 
IgG and OPA titers for all four serotypes among the control subjects with correlation 
coefficients (r) ranging from 0.51 to 0.85. In sharp contrast, the MM patients showed no 
correlation for any of the serotypes (r = -0.18 – 0.21). WM patients had borderline 
significance for two serotypes (r = 0.53 and 0.54, P = 0.06) while the MGUS patients 
resembled the control group with significant correlations for three out of four serotypes 
(r = 0.53 – 0.80). Correlation analyses for serotype 23F are shown in Figure 15. 
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 Correlation between anti-pneumococcal IgG and OPA titers for serotype 23F. MM, multiple Figure 15.
myeloma; WM, Waldenstrom’s macroglobulinemia; MGUS, monoclonal gammopathy of undetermined 
significance. Diamonds indicate patients vaccinated with the conjugated pneumococcal vaccine (PCV7), circles 
indicate patients vaccinated with the polysaccharide vaccine (PPV). 
Anti-pneumococcal IgG levels have been shown to correlate well with opsonic activity 
in vaccinated children but more poorly in the elderly population.197, 202 Romero-Steiner et 
al. found weaker correlations in a group of vaccinated elderly adults compared to 
younger adults, which was explained by lower antibody avidity among the elderly.197 We 
found good correlations among our elderly control subjects; however, their median age 
was lower (68 years) than in the group of elderly adults of the referred study (85 years). 
Discrepancies in the outcome of pneumococcal ELISA and OPA analyses as in our MM 
and WM study cohorts have previously been described in other immunocompromised 
patients such as HIV patients and renal transplant recipients.203, 204 In contrast, a study 
of allogeneic stem cell transplanted patients showed significant correlations between 
anti-pneumococcal IgG and OPA titers in 7/7 investigated serotypes.205 These patients 
were considerably younger (mean age, 37 years) than those of our study and had other 
hematological diagnoses. 
In general, elderly adults require higher IgG titers against pneumococci to achieve the 
same killing capacity as younger adults.71, 197, 198, 201 Besides a lower antibody avidity, this 
phenomenon has been ascribed to loss of oligoclonality in response to pneumococcal 
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antigens, reduced function of phagocytic cells, and decreased levels of anti-
pneumococcal IgM as a consequence of deficient IgM memory B cells with increasing 
age.71, 206, 207 We found markedly low IgM titers in the MM patients, who had the highest 
median age among our study groups but who have also been shown to have the most 
suppressed B cell memory.100, 101 In contrast, anti-pneumococcal IgM titers in WM 
patients were relatively high although it was only one serotype that correlated 
significantly with the OPA analysis. The correlation between anti-pneumococcal IgM 
and OPA titers was poor and inconsistent in all four study groups, which indicates that 
lack of IgM was not the main reason for poor OPA function in our study subjects.  
We speculate that interference of M-protein with the pneumococcal ELISA resulting in 
falsely high antibody concentrations could be a reason for the poor correlation between 
the serological and OPA analyses in our disease groups. This could also explain the high 
anti-pneumococcal IgM titers in the WM patients, who have an M-protein of IgM 
subtype. Cross-reactions with M-protein have previously been shown for a variety of 
laboratory tests including analyses of anti-streptococcal antibodies.208 Unfortunately, 
since we had too little serum left to measure the post-vaccination M-protein levels in 
our patients, we could not test this hypothesis properly. However, it is unlikely to be the 
only cause for the incongruence between the ELISA and OPA results as our MGUS 
patients exhibited nearly as good correlations as the control subjects despite relatively 
high pre-vaccination levels of M-protein. The OPA responses may also have been 
influenced by disease-related cellular immune defects, which are more profound in MM 
and WM patients than in MGUS patients.99 
In summary, this study showed that post-vaccination pneumococcal antibody titers as 
measured by serotype-specific ELISA correlated poorly with the results of a multiplex 
killing-type OPA in sera from elderly patients with a diagnosis of multiple myeloma or 
Waldenstrom’s macroglobulinemia.  
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4.4 Respiratory viruses in multiple myeloma (paper IV) 
In paper IV we retrospectively investigated the prevalence of respiratory viruses (RV) in 
nasopharyngeal samples collected from myeloma patients with respiratory symptoms 
and examined a possible association with age, sex, disease activity, disease duration, 
ASCT, sepsis (particularly of pneumococcal origin), hospitalization, and death. 
In total, 98 respiratory samples from 55 myeloma patients were identified during the 
study period. Forty-one of the samples (42%) derived from 24 of the patients (44%) 
were positive for at least one RV. This is similar to the detection rate of RVs in all 
unsorted clinical samples that were analyzed with multiplex PCR at the same laboratory 
between 2006 and 2009,209 and with previous studies using similar PCR methods and 
panels of viruses.210, 211 The most frequently detected virus in our study cohort was 
rhinovirus, followed by influenza viruses, respiratory syncytial virus (RSV), 
metapneumovirus, and parainfluenza virus (Table 3). 
Table 3. Respiratory tract viruses.  
 
Respiratory tract virus n (%) 
Rhinovirus 11 (27) 
Rhinovirus +/- enterovirus   2 (5) 
Respiratory syncytial virus    7 (17) 
Metapneumovirus   5 (12) 
Influenza A   3 (7) 
Influenza A H1N1   1 (2) 
Influenza B   3 (7) 
Influenza B + coronavirus   2 (5) 
Parainfluenza virus   4 (10) 
Adenovirus    2 (5) 
Coronavirus   1 (2) 
 
Our findings were comparable to those of two recent studies of other hematologic 
patients (allogeneic stem cell transplanted patients, hematologic patients with 
neutropenia). 212, 213 In a majority of studies, influenza viruses and RSV dominate the 
respiratory viral infectious spectrum,124, 125, 214, 215 which may in part be explained by the 
use of older detection methods such as viral culture and antigen detection. PCR 
methods have been shown to increase the diagnostic yield of respiratory viruses, not 
least of rhinovirus.216, 217 
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The seasonal distribution of viral isolates in this myeloma cohort showed the same 
pattern as in the general population of temperate climate zones,209, 214 with influenza and 
RS viruses only detected during the winter months while rhinovirus and parainfluenza 
virus were seen all year round. No epidemics of viral infections were evident in our 
study as reflected by the relatively few RV analyses that were performed during the 
study period. Myeloma patients with mild symptoms are normally advised to stay at 
home and not to seek medical care. It is also probable that a number of the patients with 
respiratory tract symptoms were not sampled regarding RVs since most of these 
infections lack a specific treatment.  
As myeloma patients have an enhanced risk of contracting bacterial respiratory 
infections,106 we expected to find positive blood cultures in relation to RV analyses, both 
representing secondary infections and differential diagnoses of viral infections. 
However, although blood cultures were taken in relation to the RV samples in 50% 
(49/98) of the cases, only two were positive, both for pneumococci, and both preceded 
by negative RV tests. One reason for the low hit rate might be that most myeloma 
patients with ongoing treatment including during the post-transplantation period receive 
antibiotic prophylaxis. 
Thirty-six of the 55 patients were sampled once for analyses of RVs, the remaining 
patients had had between two (n = 7) and eight (n = 1) analyses performed during the 
study period. Seventeen of the patients were female (31%) and 38 male (69%). Multiple 
myeloma is slightly more prevalent in men than in women;14 however, the male 
predominance is less than what was seen in the RV sampling which could indicate a true 
gender difference regarding infectious susceptibility or the proneness of the care 
provider to order these virological analyses. 
When comparing patients with and without virus-positive respiratory specimens only 
two factors displayed a significant difference between the groups: the virus-positive 
patients were younger (median age 58 years vs. 61 years; P = 0.01) and had shorter 
disease duration at the time of sampling (653 days vs. 1177 days; P = 0.04). The latter is 
in accordance with the fact that the incidence of bacterial as well as viral infections in 
myeloma patients is the highest during the first months after diagnosis.106, 110  
The incidence of leukopenia (WBC < 3 x 109 L-1) was equal in the patients with and 
without positive RV analyses (24% and 23%, respectively). Lymphopenia and 
neutropenia have previously been identified as risk factors of severe RV infections.124, 215  
Unfortunately, it was not possible to evaluate the role of specific white blood cells since 
blood differential counts were missing in many of our cases, but there was a slight trend 
towards lower WBC in the patients with at least one positive RV sample. In contrast, 
and in opposition to what we expected, there was a clear tendency towards higher levels 
of M-protein (median 19 vs. 7.0 g/L; P = 0.08) and lower S-IgG (median 3.3 vs. 4.0 
g/L; P = 0.16) in patients with only virus-negative analyses. Possibly, these patients with 
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more advanced disease were less active and therefore less exposed to community-
acquired infectious agents. Additionally, they may have been more liberally sampled for 
infectious agents as a consequence of their immunosuppression. 
Two thirds of the patients had undergone ASCT at the time of viral sampling with a 
tendency towards higher transplantation rates in patients with positive RV analyses 
(79% vs. 58%; P = 0.15). In a recent study of myeloma patients undergoing ASCT, one 
third of the patients experienced at least one infectious episode during the first month 
after transplantation, most commonly a respiratory tract infection with influenza virus 
and pneumococci as the predominantly identified pathogens.126 
Fifty-three of the RV samples (54%) were collected in hospitalized patients; twenty 
(38%) of these were positive with influenza viruses, RSV and rhinovirus being the most 
common pathogens. Previous studies have reported high frequencies of hospitalization 
and prolonged hospital stay in patients with hematological malignancies and influenza or 
RSV infection.127, 214 We did not find a significant difference in the duration of 
hospitalization between patients with and without findings of RV in their respiratory 
secretions. However, since hospitalizations in our study were due not only to infection 
but also to ASCT and the administration of chemotherapy it is likely that fever and 
respiratory symptoms had other causes besides infectious complications. 
Overall mortality in the study was 47%. Thirteen of the 55 patients (24%) died within 
three months after a RV analysis, however without a difference between patients with 
virus-positive and virus-negative samples. Survival analyses could not prove a statistical 
significance between patients with ≥ 1 RV positive specimen vs. patients with only 
negative specimens but when looking at 50% survival there was a 400-600 days 
advantage for the test-negative patients (Figure 16). The trend towards higher mortality 
in patients positive for respiratory viruses, who also had shorter disease duration, is in 
accordance with the findings of Blimark et al. describing an infection-related mortality of 
22% one year after the myeloma diagnosis.110 
In summary, this retrospective study showed the same detection rate and pattern of 
respiratory viruses as in the general population. Myeloma patients with at least one 
virus-positive respiratory sample had lower median age and shorter disease duration 
than patients with no positive samples. Duration of hospitalization and mortality did not 
differ significantly between the groups. 
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 Overall survival for patients with ≥ 1 positive respiratory virus sample vs. patients with no Figure 16.
positive sample. The last positive sample for each patient in the virus-positive group of patients was compared 
to the last negative test for each patient in the virus-negative group. 
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4.5 Methodological considerations 
A limitation of the studies described in papers I-III was the relatively few individuals in 
each study group, especially in paper II where each study group was subdivided into two 
vaccine groups (PCV7 vs. PPV). However, the studies comprise diagnoses (MGUS, 
WM) and subgroups of patients (elderly, non stem-cell transplanted) who have 
previously been sparsely investigated regarding humoral immunity and vaccine 
responsiveness. Since the prevalence of these B cell disorders is low, especially WM,  
larger cohorts would probably have required a multi-center strategy, which is desirable 
for future studies not least in the evaluation of vaccine responses.  
In papers I-III there was a discrepancy between the median ages in the study groups 
such that the MM and WM patients were older than the MGUS patients and the control 
subjects. The differences were significant in paper III but not in paper I and II. 
However, this might still have affected the outcome of vaccination as well as the 
serological and OPA results with poorer responses and titers in the more diseased (and 
older) study groups. 
The clinical data in papers I-III were retrieved from a patient questionnaire and from 
medical records retrospectively. This is a limitation since the information is dependent 
on correct documentation and self reports on vaccination status, which are often not 
reliable.  
In paper II, the choice of single-dose vaccination may be considered as controversial 
regarding the conjugated vaccine since the vaccine effect is boostable and current 
recommendations advise one dose of PCV13 followed by one dose of PPV in 
immunocompromised adults.137 This is the preferred strategy in order to broaden 
serotype coverage in risk groups. However, as discussed in the results section, at the 
time of our study the vaccination regime in our region comprised a single dose of PPV 
for these patients, and we wished to evaluate if a single dose of PCV7 would result in an 
improved response to the included serotypes. Other limitations of the pneumococcal 
vaccination study include the absence of a long-term follow-up of the vaccine responses, 
and the use of an ELISA method which did not employ pre-adsorption of serotype 22F 
polysaccharide. The latter intervention has been shown to reduce the effect of cross-
reacting, non-functional pneumococcal antibodies especially in pre-immunization 
sera.218  Further, there was a relatively wide interval between the vaccination and the 
follow-up sampling (4-8 weeks); however, the number of days showed no association 
with post-vaccination OPA titers in neither the multivariate nor in the univariate 
analyses. Paper II comprised multiple statistical analyses and a post-hoc test was 
considered to reduce the risk of type I error. Since this was not applied in the majority 
of similar refereed vaccine studies, we chose not to do so either but to use the same 
statistical methods and significance level (0.05) to be able to compare our results.  
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A draw-back of paper III is the fact that we were not able to perform analyses of post-
vaccination levels of M-protein in the disease groups. This would have been required to 
test the hypothesis of interference of the M-protein with the ELISA analyses as a reason 
for the poor correlations between ELISA and OPA results in the MM and WM patients. 
Another limitation is the use of different laboratories, time-points and methods for the 
ELISA IgG and IgM analyses. However, both assays were accredited and performed at 
pneumococcal reference laboratories. The results were not compared with each other 
but only with the OPA responses.  
The limitations of paper IV include the retrospective nature of the study and the 
relatively low number of respiratory virus samples and patients, which may reflect that 
clinicians were not prone to order the analyses and/or did not consider respiratory 
viruses to be of clinical significance in myeloma patients. A larger number of samples 
would have allowed for more comparisons between the detected viruses, and larger 
patient groups would probably have resulted in clearer differences between patients with 
positive RV analyses vs. patients with only virus-negative samples. The differing 
numbers of respiratory samples collected from the study patients may have skewed the 
data. Further, the successive expansion of viruses detected by the multiplex PCR 
method in use during the study period should have influenced the outcome. Finally, we 
did not investigate the association between virus positivity and immunosuppressive 
treatment regimens other than ASCT or gather information on symptoms and causes of 
death, which would be valuable to include as study parameters, especially in a larger 
patient cohort.  
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5 Conclusions 
Background antibody levels to a large number of microbial pathogens are depressed in 
patients with B cell malignancies and disorders indicative of an increased infectious 
susceptibility. This is seen primarily in MM patients but also in patients with WM and 
MGUS. We identified pneumococci, S. aureus, VZV, and fungi (Candida, Aspergillus) as 
risk pathogens. In contrast, humoral immunity to H. influenzae type B and most viral 
agents was retained in these groups of patients. 
Antibody responses to pneumococcal vaccination as measured by serotype-specific 
ELISA and opsonophagocytosis are suppressed not only in MM patients but also in 
WM and MGUS. A single dose of conjugated pneumococcal vaccine (PCV7) was not 
superior to the polysaccharide vaccine (PPV) in our study cohorts. Hypogamma-
globulinemia and ongoing chemotherapy were associated with poor vaccine responses in 
a multivariate model. 
Pneumococcal antibody titers as measured by serotype-specific IgG and IgM ELISA 
correlate poorly with the results of a killing-type opsonophagocytosis assay (OPA) in 
patients with MM and WM. Our data suggest that ELISA measurements may 
overestimate anti-pneumococcal immunity in patients with B cell malignancies. The use 
of an OPA method should be preferred for evaluating pneumococcal vaccine responses 
in these patients. 
Rhinovirus, influenza viruses, and RSV were the most commonly detected respiratory 
viruses in a retrospective study of MM patients. Patients with virus-positive tests were 
younger and had shorter disease duration than virus-negative patients. Duration of 
hospitalization and mortality did not differ significantly between the groups. Although 
MM patients have an increased risk of RV infections we did not confirm a major impact 
on morbidity and mortality; however, this needs to be evaluated in larger studies. 
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6 Future perspectives 
Patients with multiple myeloma, Waldenstrom’s macroglobulinemia and MGUS are risk 
groups of contracting and succumbing to infections. Increased knowledge of the 
spectrum of pathogens, vaccine responses as well as timing of infections and additional 
risk factors are needed to improve preventive strategies against infections in these 
patients.  
Regarding pneumococcal vaccination of patients with B cell malignancies, the timing of 
vaccination in relation to disease stage, treatment, and ASCT remains to be elucidated. 
The finding of augmented pneumococcal vaccine responses in lenalidomide-treated 
myeloma patients indicates a possible vaccine adjuvant function of this class of drugs,140 
which definitely merits extended investigations. Awaiting future generations of 
pneumococcal vaccines, the existing conjugate and polysaccharide formulations should 
be used in series in these patients. Further studies are required to investigate if there 
would be a benefit of repeat doses of PCVs followed by the polysaccharide vaccine in 
patients with B cell malignancies. Such studies should include ASCT recipients, since 
current recommendations on pneumococcal vaccination in these patients are largely 
based on studies of allogeneic stem cell transplanted patients.  Considering the role of 
immunodeficiency in B cell disorders with respect to vaccine responses, it would be of 
interest to further investigate B cell subsets, for example IgM memory B cells, which are 
of major importance in the response to polysaccharide vaccines.71  
When comparing pneumococcal ELISA and OPA results we found a very poor 
correlation between the analyses in MM and WM patients. It would be desirable to 
investigate if our results are reproducible in a larger patient cohort and also in other 
hematological conditions, for instance chronic lymphatic leukemia. It would also be of 
interest to test our hypothesis of interference of M-protein with the pneumococcal 
ELISA analyses, which would require measurement of post-vaccination M-protein levels 
in parallel with antibody and OPA titers.  
In order to better study the prevalence of and morbidity from respiratory viruses in B 
cell disorders a larger study, preferably prospective, with addition of data regarding 
causes for hospitalization and death is warranted.  
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